Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.
Infections with bacteria of the species NEISSERIA MENINGITIDIS.
A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8)
A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype.
Strains of Neisseria meningitidis which are the most common ones causing infections or disease in infants. Serogroup B strains are isolated most frequently in sporadic cases, and are less common in outbreaks and epidemics.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Strains of Neisseria meningitidis responsible for most sporadic cases in teenagers and almost all outbreaks of disease in this age group. These strains are less common in infants.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
The natural bactericidal property of BLOOD due to normally occurring antibacterial substances such as beta lysin, leukin, etc. This activity needs to be distinguished from the bactericidal activity contained in a patient's serum as a result of antimicrobial therapy, which is measured by a SERUM BACTERICIDAL TEST.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Porins are protein molecules that were originally found in the outer membrane of GRAM-NEGATIVE BACTERIA and that form multi-meric channels for the passive DIFFUSION of WATER; IONS; or other small molecules. Porins are present in bacterial CELL WALLS, as well as in plant, fungal, mammalian and other vertebrate CELL MEMBRANES and MITOCHONDRIAL MEMBRANES.
Substances elaborated by bacteria that have antigenic activity.
A class of carrier proteins that bind to TRANSFERRIN. Many strains of pathogenic bacteria utilize transferrin-binding proteins to acquire their supply of iron from serum.
Proteins isolated from the outer membrane of Gram-negative bacteria.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
Polysaccharides found in bacteria and in capsules thereof.
Schedule giving optimum times usually for primary and/or secondary immunization.
Two or more vaccines in a single dosage form.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host.
An important soluble regulator of the alternative pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It is a 139-kDa glycoprotein expressed by the liver and secreted into the blood. It binds to COMPLEMENT C3B and makes iC3b (inactivated complement 3b) susceptible to cleavage by COMPLEMENT FACTOR I. Complement factor H also inhibits the association of C3b with COMPLEMENT FACTOR B to form the C3bB proenzyme, and promotes the dissociation of Bb from the C3bBb complex (COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY).
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
Process of determining and distinguishing species of bacteria or viruses based on antigens they share.
Ability of a microbe to survive under given conditions. This can also be related to a colony's ability to replicate.
Strains of Neisseria meningitidis responsible for most outbreaks of meningococcal disease in Western Europe and the United States in the first half of the 20th century. They continue to be a major cause of disease in Asia and Africa, and especially localized epidemics in Sub-Sahara Africa.
Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
Proteins found in any species of bacterium.
Strains of Neisseria meningitidis found mostly in Africa.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
Strains of Neisseria meningitidis which, in the United States, causes disease in mostly adults and the elderly. Serogroup Y strains are associated with PNEUMONIA.
A species of gram-negative, aerobic BACTERIA commonly found in the NASOPHARYNX of infants and children, but rarely pathogenic. It is the only species to produce acid from LACTOSE.
Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS.
The non-susceptibility to infection of a large group of individuals in a population. A variety of factors can be responsible for herd immunity and this gives rise to the different definitions used in the literature. Most commonly, herd immunity refers to the case when, if most of the population is immune, infection of a single individual will not cause an epidemic. Also, in such immunized populations, susceptible individuals are not likely to become infected. Herd immunity can also refer to the case when unprotected individuals fail to contract a disease because the infecting organism has been banished from the population.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.
Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.
A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)
Procedures for identification and measurement of IMMUNOGLOBULINS in the blood that initiate lysis of bacteria.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.
An envelope of loose gel surrounding a bacterial cell which is associated with the virulence of pathogenic bacteria. Some capsules have a well-defined border, whereas others form a slime layer that trails off into the medium. Most capsules consist of relatively simple polysaccharides but there are some bacteria whose capsules are made of polypeptides.
Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.
A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.
The formaldehyde-inactivated toxin of Corynebacterium diphtheriae. It is generally used in mixtures with TETANUS TOXOID and PERTUSSIS VACCINE; (DTP); or with tetanus toxoid alone (DT for pediatric use and Td, which contains 5- to 10-fold less diphtheria toxoid, for other use). Diphtheria toxoid is used for the prevention of diphtheria; DIPHTHERIA ANTITOXIN is for treatment.
Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.
Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.
Administration of a vaccine to large populations in order to elicit IMMUNITY.
Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.
Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.
A republic in western Africa, north of NIGERIA and west of CHAD. Its capital is Niamey.
Vaccines or candidate vaccines used to prevent ANTHRAX.
Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.
Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Method of measuring the bactericidal activity contained in a patient's serum as a result of antimicrobial therapy. It is used to monitor the therapy in BACTERIAL ENDOCARDITIS; OSTEOMYELITIS and other serious bacterial infections. As commonly performed, the test is a variation of the broth dilution test. This test needs to be distinguished from testing of the naturally occurring BLOOD BACTERICIDAL ACTIVITY.
Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is >2-3 cm it is generally called Ecchymoses (ECCHYMOSIS).
A genus of gram-negative, aerobic, coccoid bacteria whose organisms are part of the normal flora of the oropharynx, nasopharynx, and genitourinary tract. Some species are primary pathogens for humans.
The top portion of the pharynx situated posterior to the nose and superior to the SOFT PALATE. The nasopharynx is the posterior extension of the nasal cavities and has a respiratory function.
Any vaccine raised against any virus or viral derivative that causes hepatitis.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.
A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.
A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.

Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta. (1/586)

Children with frequent recurrent episodes of otitis media may have a deficient IgG2 antibody response to polysaccharide antigens. Five otitis-prone children were vaccinated with heptavalent pneumococcal conjugate vaccine. While all had an IgG1 antibody response to all pneumococcal serotypes included in the conjugate vaccine, the IgG2 response, especially to serotypes 6B, 9V, 19F, and 23F, was poor. However, vaccination with a 23-valent polysaccharide vaccine 6 months after conjugate vaccination induced an 11.5- to 163-fold increase in IgG2 anti-polysaccharide antibody titers. Thus, an IgG2 polysaccharide antibody deficiency can be overcome by priming with a pneumococcal conjugate vaccine followed by a booster with a polyvalent polysaccharide vaccine.  (+info)

Humoral immune responses to Neisseria meningitidis in children. (2/586)

An understanding of the nature of immunity to serogroup B meningococci in childhood is necessary in order to establish the reasons for poor responses to candidate vaccines in infancy. We sought to examine the nature of humoral immune responses following infection in relation to age. Serum bactericidal activity was poor in children under 12 months of age despite recent infection with Neisseria meningitidis. The highest levels of bactericidal activity were seen in children over 10 years of age. However, infants produced levels of total immunoglobulin G (IgG) and IgG subclass antibodies similar to those in older children in a meningococcal enzyme-linked immunosorbent assay. Most antibody was of the IgG1 and IgG3 subclasses. This striking age dependency of bactericidal antibody response following infection is not apparently due to failure of class switching in infants but might be due to qualitative differences in antibody specificity or affinity.  (+info)

Cellular immune responses to Neisseria meningitidis in children. (3/586)

There is an urgent need for effective vaccines against serogroup B Neisseria meningitidis. Current experimental vaccines based on the outer membrane proteins (OMPs) of this organism provide a measure of protection in older children but have been ineffective in infants. We postulated that the inability of OMP vaccines to protect infants might be due to age-dependent defects in cellular immunity. We measured proliferation and in vitro production of gamma interferon (IFN-gamma), tumor necrosis factor alpha, and interleukin-10 (IL-10) in response to meningococcal antigens by peripheral blood mononuclear cells (PBMCs) from children convalescing from meningococcal disease and from controls. After meningococcal infection, the balance of cytokine production by PBMCs from the youngest children was skewed towards a TH1 response (low IL-10/IFN-gamma ratio), while older children produced more TH2 cytokine (higher IL-10/IFN-gamma ratio). There was a trend to higher proliferative responses by PBMCs from older children. These responses were not influenced by the presence or subtype of class 1 (PorA) OMP or by the presence of class 2/3 (PorB) or class 4 OMP. Even young infants might be expected to develop adequate cellular immune responses to serogroup B N. meningitidis vaccines if a vaccine preparation can be formulated to mimic the immune stimulus of invasive disease, which may include stimulation of TH2 cytokine production.  (+info)

Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. (4/586)

The safety, immunogenicity, and immunologic priming of 2 dosages (2 microgram or 10 microgram) of a meningococcal C oligosaccharide-CRM197 conjugate vaccine was evaluated in 114 infants vaccinated at ages 2, 3, and 4 months. Antibody persistence and response to boosting with 10 microgram of meningococcal C polysaccharide were assessed. The meningococcal conjugate vaccine produced fewer local reactions than concurrent routine immunizations. Total serogroup C-specific immunoglobulin geometric mean concentration (GMC) increased from 0.3 microgram/mL before vaccination to 13.1 microgram/mL at age 5 months. Serum bactericidal antibody (SBA) geometric mean titers (GMTs) rose from <1:4 to 1:1057 at 5 months and fell by 14 months to 1:19. Following boosting, anti-C-specific immunoglobulin GMC rose to 15.9 microgram/mL and SBA GMT to 1:495. Antibody responses in the 10-microgram dose cohort were significantly higher at 5 months (P<.01) than in the 2-microgram dose cohort but were lower after polysaccharide boosting (P=.02). This meningococcal conjugate vaccine was well tolerated and immunogenic and induced immunologic memory in infants.  (+info)

Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. (5/586)

We measured the capacity to opsonize Streptococcus pneumoniae serotype 6B and estimated the concentration of immunoglobulin G anti-6B capsular polysaccharide (PS) antibodies in 25 pre- and postimmune sera from adults immunized with a pneumococcal PS vaccine. We first studied two postvaccination serum samples displaying less opsonophagocytic capacity than expected. The majority of anti-6B antibodies in the two samples reacted with the capsular PSs of several unrelated serotypes (2, 4, 9V, 19F, and 23F) and with the lysate of noncapsulated S. pneumoniae bacteria but not with C-PS. The non-type-specific antibodies accounted for at least one-half of anti-6B antibodies in 40% of prevaccination sera and 10% of postvaccination sera from adults. The non-type-specific antibodies could be demonstrated in the enzyme-linked immunosorbent assays (ELISAs) for pneumococcal antibodies to other serotypes (4, 9V, 18C, 19F, and 23F). The nonspecific antibodies appear to bind a contaminant(s) in the current preparations of capsular PS. ELISA for antibodies to pneumococcal capsules may not be serotype specific for some samples.  (+info)

Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. (6/586)

We compared responses to pneumococcal conjugate and polysaccharide vaccines in 48 otitis-free and 64 otitis-prone children. Pre- and postimmunization concentrations of antibodies to pneumococcal serotypes 6B, 14, 19F, and 23F were measured by enzyme-linked immunosorbent assay. Postimmunization mean concentrations of antibodies to all four serotypes were significantly higher for children receiving conjugate vaccine than for those receiving polysaccharide vaccine; the difference in responses was primarily due to a better response to conjugate vaccine in the otitis-prone group. Significantly higher postimmunization concentrations of antibodies to all four serotypes and to one of the four serotypes were found in otitis-prone children and otitis-free children who received conjugate vaccine, respectively. Pneumococcal conjugate vaccine has the potential to reduce the incidence of disease due to vaccine serotypes, even among children with recurrent otitis media.  (+info)

Fcgamma receptor polymorphisms determine the magnitude of in vitro phagocytosis of Streptococcus pneumoniae mediated by pneumococcal conjugate sera. (7/586)

Fcgamma receptors show two genetically determined polymorphisms: the biallelic FcgammaRIIa-R131 and -H131 polymorphism and the NA1/NA2 FcgammaIIIb polymorphism. Using 10 pre- and postconjugate vaccination sera from adults, we analyzed in vitro phagocytic capacities of three different combinations of polymorphonuclear leukocyte FcgammaR allotypes: those homozygous for the H131 and NA1 allotype, those homozygous for the R131 and NA2 allotype, and those heterozygous for both receptors. For pre- and postvaccination sera, mean phagocytosis levels for the homozygous H131/NA1 allotype were 4 -fold higher than for the homozygous R131/NA2 allotype. There was a strong and significant correlation between IgG2 ELISA antibody titers and phagocytosis levels for the homozygous H131/NA1 Fcgamma receptor allotype and the heterozygous allotype but not for the homozygous R131/NA2 allotype. There was no relation between IgG1 ELISA titer and phagocytosis level. Apparently the IgG2 antibodies induced are functionally the most important. This may explain the large effect of Fcgamma receptor polymorphisms on in vitro phagocytosis of pneumococci mediated by conjugate antisera.  (+info)

The epidemiological impact of antimeningococcal B vaccination in Cuba. (8/586)

The incidence of invasive meningococcal disease (IMD) before (1984-1988) and after (1989-1994), a nationwide intervention with VA-MENGOC-BC vaccination started in 1989, was compared. The prevaccination period incidence density (ID> 8.8/10(5) year-person) was higher than the postvaccination ID (ID< 6.5/10(5) year-person). The percentage proportional differences from the start to the end of each period of ID in the vaccinal period was higher (87%) than the prevaccinal (37%) with significant differences among vaccinated groups (< 25 years old). A break-point (Chow test) was confirmed by the decrease in the ID between 1989 and 1990 in children under 1 year old, 5-9, 10-14, 15-19 and 50-54 years. Comparison of ID using maps showed a decrease in IMD in all municipalities during the postvaccination period. These findings support the epidemiological impact of VA-MENGOC-BC vaccination in the reduction of IMD morbidity.  (+info)

OBJECTIVE: To determine the persistence of bactericidal antibody titres following immunisation with serogroup C meningococcal glycoconjugate vaccine at age 6-15 years in order to examine changes in persistence of antibodies with age. DESIGN: Observational study. SETTING: Secondary and tertiary educational institutions in the United Kingdom. PARTICIPANTS: Healthy adolescents aged 11-20 years previously immunised between 6 and 15 years of age with one of the three serogroup C meningococcal vaccines. INTERVENTION: Serum obtained by venepuncture. MAIN OUTCOME MEASURES: Percentage of participants with (rabbit complement) serum bactericidal antibody titres of at least 1:8; geometric mean titres of serogroup C meningococcal serum bactericidal antibody. RESULTS: Five years after immunisation, 84.1% (95% confidence interval 81.6% to 86.3%) of 987 participants had a bactericidal antibody titre of at least 1:8. Geometric mean titres of bactericidal antibody were significantly lower in 11-13 year olds (147, 95%
In January 2011, the Food and Drug Administration lowered the approval age range for use of MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics), a quadrivalent meningococcal conjugate vaccine, to include persons aged 2 through 55 years. One other quadrivalent meningococcal conjugate vaccine, MenACWY-D(Menactra, Sanofi Pasteur), is licensed in the United States for prevention of meningococcal disease caused by serogroups A, C, Y, and W-135 among persons aged 2 through 55 years; MenACWY-D also is licensed as a 2-dose series for children aged 9 through 23 months (1,2). The Advisory Committee on Immunization Practices (ACIP) recommends that persons aged 2 through 55 years at increased risk for meningococcal disease and all adolescents aged 11 through 18 years be immunized with meningococcal conjugate vaccine. ACIP further recommended, in January 2011, that all adolescents receive a booster dose of quadrivalent meningococcal conjugate vaccine at age 16 years (3). This report summarizes data ...
We have demonstrated the high specificity of the rSBA in young children who have not been previously vaccinated with MenC polysaccharide or MCC vaccines and could therefore be presumed to be susceptible to MenC infection. Therefore, rSBA titers of ,8 predict susceptibility. This conclusion was corroborated in a recent university outbreak of MenC disease in which rSBA titers in students prior to or at the onset of invasive disease were all ,4, suggesting that it is the absence of bactericidal activity is that is important irrespective of the complement source used (22). We have also shown that rSBA titers of ≥128 are highly predictive of protection but that many sera with rSBA titers in the range 8 to 64 also come from individuals with protection, particularly for adults with natural exposure. The main issue is therefore the interpretation of rSBA titers in the region of 8 to 64. For groups in whom there is likely to be a large proportion of results in this range, it is important to have other ...
We conducted a large-scale cohort study in a real-world setting to evaluate the safety of 1 of the currently available quadrivalent meningococcal conjugate vaccines in the United States, MenACWY-CRM. The population includes individuals receiving the vaccine, as a first dose or a booster dose, at the recommended age of 11 to 18 years old, as well as young adults through 21 years old who are at an increased risk of invasive meningococcal infection. We were able to confirm the diagnosis, determine the onset date, and identify alternative causes of the events using EHRs. The within-person comparison inherent to the SCCS design allowed for control of potential confounders. We observed a temporal association between occurrence of Bells palsy and receipt of MenACWY-CRM concomitantly with other vaccines. Three of the 8 Bells palsy patients in the risk window had comorbidities and infections that could be a prelude to the condition. All 8 cases resolved completely.. The etiology and pathogenesis of ...
The maintenance of adequate serum Ab levels following immunization has been identified as the most important mechanism for individual long-term protection against rapidly invading encapsulated bacteria. The mechanisms for maintaining adequate serum Ab levels and the relationship between Ag-specific memory B cells and Ab at steady state are poorly understood. We measured the frequency of circulating serogroup C meningococcal (MenC)-specific memory B cells in 250 healthy 6- to 12-y-old children 6 y following MenC conjugate vaccine priming, before a booster of a combined Haemophilus influenzae type b-MenC conjugate vaccine and then 1 wk, 1 mo, and 1 y after the booster. We investigated the relationship between circulating MenC-specific memory B cell frequencies and Ab at baseline and following the booster vaccine. We found very low frequencies of circulating MenC-specific memory B cells at steady state in primary school-aged children and little association with MenC IgG Ab levels. Following ...
The primary aim of this study was to determine whether, in preschool children and school leavers, administration of diphtheria and tetanus booster vaccines at the same time, before, or after meningococcal conjugate vaccine had an effect (positive or negative) on the immune responses to any vaccine. No clinically relevant negative interactions were identified, and in all groups immune responses that were indicative of protection developed against the diphtheria, tetanus, and meningococcal antigens in all or almost all children.. The only adverse effect on immunogenicity of the MCC vaccines arising from an interaction was seen with the MCC-TT vaccine, where rSBA and IgG levels were reduced (although not below the protective threshold) by prior and, to a lesser extent, by concomitant administration of DT or Td vaccine. This phenomenon, termed carrier-induced epitopic suppression, has previously been described in the context of conjugate vaccines (1) and is thought to be due to the expansion of ...
On October 27, 2010, the Advisory Committee on Immunization Practices (ACIP) approved updated recommendations for the use of quadrivalent (serogroups A, C, Y, and W-135) meningococcal conjugate vaccines (Menveo, Novartis; and Menactra, Sanofi Pasteur) in adolescents and persons at high risk for meningococcal disease. These recommendations supplement the previous ACIP recommendations for meningococcal vaccination (1,2). The Meningococcal Vaccines Work Group of ACIP reviewed available data on immunogenicity in high-risk groups, bactericidal antibody persistence after immunization, current epidemiology, vaccine effectiveness (VE), and cost-effectiveness of different strategies for vaccination of adolescents. The Work Group then presented policy options for consideration by the full ACIP. This report summarizes two new recommendations approved by ACIP: 1) routine vaccination of adolescents, preferably at age 11 or 12 years, with a booster dose at age 16 years and 2) a 2-dose primary series ...
BACKGROUND: The persistence of protection from meningococcal disease following immunization with serogroup C meningococcal (MenC) glycoconjugate vaccines in infancy is short-lived. The duration of protective immunity afforded by these vaccines in other at-risk age groups (i.e., adolescents and young adults) is not known. We evaluated the persistence of bactericidal antibodies following immunization with a MenC glycoconjugate vaccine (MenCV) in adolescents and the kinetics of immune response to a meningococcal AC plain polysaccharide vaccine (MenPS) challenge or a repeat dose of MenCV. METHODS: We conducted a randomized comparative trial of 274 healthy 13-15-year-olds from whom a total of 4 blood samples were obtained (prior to administration of a dose of MenPS or MenCV, again on 2 further occasions at varying times from days 2-7 after vaccination, and finally on day 28 after vaccination. The correlate of protection was a serum bactericidal assay titer | or = 8 (with a serum bactericidal assay using
BACKGROUND: The highest rate of invasive meningococcal disease is among children under 2 years of age. There is currently no licensed quadrivalent (serogroups A, C, W-135, and Y) meningococcal glycoconjugate vaccine approved for infants. We evaluated the immunogenicity and reactogenicity of a novel quadrivalent nonadjuvanted meningococcal glycoconjugate vaccine (MenACWY-CRM) in healthy infants. METHODS: One hundred eighty infants (90 in Canada and 90 in the United Kingdom) received 2 doses of MenACWY-CRM at 2 and 4 months of age administered concomitantly with routine infant vaccines. At 12 months of age, the Canadian infants received either MenACWY-CRM or a reduced dose of a licensed meningococcal polysaccharide vaccine. In the United Kingdom, all infants received a further dose of MenACWY-CRM. The serological marker of protection was a titer of | or =1:4 using a serum bactericidal assay with human complement (hSBA). RESULTS: Two doses of MenACWY-CRM induced hSBA titers | or =1:4 in 57% (95% confidence
BACKGROUND:: The highest rate of invasive meningococcal disease is among children under 2 years of age. There is currently no licensed quadrivalent (serogroups A, C, W-135, and Y) meningococcal glycoconjugate vaccine approved for infants. We evaluated the immunogenicity and reactogenicity of a novel quadrivalent nonadjuvanted meningococcal glycoconjugate vaccine (MenACWY-CRM) in healthy infants. METHODS:: One hundred eighty infants (90 in Canada and 90 in the United Kingdom) received 2 doses of MenACWY-CRM at 2 and 4 months of age administered concomitantly with routine infant vaccines. At 12 months of age, the Canadian infants received either MenACWY-CRM or a reduced dose of a licensed meningococcal polysaccharide vaccine. In the United Kingdom, all infants received a further dose of MenACWY-CRM. The serological marker of protection was a titer of ≥1:4 using a serum bactericidal assay with human complement (hSBA). RESULTS:: Two doses of MenACWY-CRM induced hSBA titers ≥1:4 in 57% (95% confidence
Safety was assessed as the number of subjects who reported solicited local and systemic adverse events following a single injection with either MenC-CRM LIQ or MenC-CRM ROS or MenC-CRM EMV.. Safety was also assessed in subjects who mistakenly received MenC-CRM EMV instead of MenC-CRM ROS. ...
Most likely, the student received a dose of the quadrivalent meningococcal conjugate vaccine (MCV4). There are 2 conjugate vaccines: Menactra (MCV4P) and Menveo (MCV4O). If the lot # is included on the record, you can determine which vaccine the student received. Menactra is a Sanofi Pasteur product and lot #s typically begin with a U. Menveo is a product from Novartis and lot #s begin with the letter M. If the lot # is not available, you may document the dose using either MCV4P or MCV4O; use MCV4P if the vaccine was administered prior to March 2010. Only doses of meningococcal vaccine administered on or after the 10th birthday meet the school requirements. Any dose of meningococcal vaccine administered prior to 2006 is the meningococcal polysaccharide vaccine (MPSV4). If a child received the meningococcal vaccine overseas, and the record does not specify MCV4, please contact the ISDH Immunization Division for further guidance.. 19. If a child receives one dose of Varicella vaccine and ...
Physician reviewed meningococcal polysaccharide vaccine patient information - includes meningococcal polysaccharide vaccine description, dosage and directions.
Background: In the absence of a serogroup B meningococcal vaccine, quadrivalent vaccines against serogroups A,C,W-135 & Y offer the broadest possible protection against disease. Both conjugate and polysaccharide quadrivalent meningococcal vaccines are licensed for use in the UK. However, polysaccharide vaccines have been associated with poor immune responses and hyporesponsiveness. Objective: To investigate polysaccharide-induced hyporesponsiveness by measuring the antibody responses to a quadrivalent meningococcal conjugate vaccine and a quadrivalent plain polysaccharide vaccine. Methods: We conducted an open-label parallel group randomised clinical trial in 150 healthy adult volunteers aged 18-70 between June 2009 and October 2010 in Oxfordshire, UK (Figure 1). Participants were randomised to receive either two doses of a conjugate quadrivalent ACWY vaccine 28 days apart (Group 1, n = 75), or one dose of a polysaccharide quadrivalent ACWY vaccine followed by one dose of a conjugate quadrivalent ACWY
TY - JOUR. T1 - Immunogenicity of the meningococcal polysaccharide conjugate vaccine in pediatric kidney transplant patients. AU - Nelson, Delphine R.. AU - Fadrowski, Jeffrey J.. AU - Neu, Alicia M. PY - 2018/3/20. Y1 - 2018/3/20. N2 - Background: Immunosuppressed kidney transplant patients may have suboptimal response to vaccinations. The aim of this study was to determine antibody response to a quadrivalent meningococcal conjugate vaccine (MenACWY-D) in adolescents with a kidney transplant. Methods: This was a prospective, single-center, cohort study. Adolescent patients (11-22 years old) with a functioning kidney transplant for at least 3 months and no previous meningococcal vaccination were eligible for enrollment. Antibody levels to all serogroups were measured before vaccination (baseline) and at 4 weeks and 1, 2 and 3 years after vaccination. Seropositivity was defined as a titer ≥ 1:8 at baseline, and seroconversion as a fourfold or greater increase in antibody titer from baseline at ...
Clinical trial phase I, randomized, double blind, where 30 individuals will receive the experimental vaccine while 30 other volunteers will receive a meningococcal C conjugate vaccine already licensed in Brazil and available in the National Immunization Program for children less than 12 months of age. The primary outcome of the study is to evaluate the safety profile of the vaccine under test, which should allow its application in humans. Secondly, the investigators will study its immunogenicity from the evaluation of the correlates of seroprotection for meningococcal, defined by the World Health Organization (WHO ...
Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine - Building on the companys successful history in developing vaccines against similar viruses, most recently the introduction of Dengvaxia® against dengue, Sanofi Pasteur is launching a Zika vaccine project - Lyon, France - February 2, 2016 - Sanofi Pasteur, the vaccines division of Sanofi, announced today that it has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease.. Sanofi Pasteur leads the vaccine field for viruses in the same family as Zika virus (ZIKV), with licensed vaccines against Yellow Fever, Japanese Encephalitis and, most recently, Dengue. Importantly, Sanofi Pasteurs expertise and established R&D and industrial infrastructure for the newly licensed vaccine for dengue, Dengvaxia®, can be rapidly leveraged to help understand the spread of ZIKV and potentially speed identification of a vaccine candidate for further clinical development. Our ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Meningococcal conjugate vaccines are today successfully deployed in universal programs for children and adolescents in different geographic regions to control meningitis and septicemia. However, in adults, the advantages of these conjugates over the older polysaccharide vaccines are less clear. In this randomized clinical trial, we demonstrated that both conjugate and polysaccharide quadrivalent meningococcal vaccines elicit protective antibody responses in adults aged 18 to 70. (This study has been registered at www.clinicaltrials.gov under registration no. NCT00901940.).
your preteen or teen shouldnt get the meningococcal vaccine if he: *has had a severe, life-threatening allergic reaction to a meningococcal vaccine before or to any vaccine component *is moderately
BACKGROUND: Herd immunity is important in the effectiveness of conjugate polysaccharide vaccines against encapsulated bacteria. A large multicenter study investigated the effect of meningococcal serogroup C conjugate vaccine introduction on the meningococcal population. METHODS: Carried meningococci in individuals aged 15-19 years attending education establishments were investigated before and for 2 years after vaccine introduction. Isolates were characterized by multilocus sequence typing, serogroup, and capsular region genotype and changes in phenotypes and genotypes assessed. RESULTS: A total of 8462 meningococci were isolated from 47 765 participants (17.7%). Serogroup prevalence was similar over the 3 years, except for decreases of 80% for serogroup C and 40% for serogroup 29E. Clonal complexes were associated with particular serogroups and their relative proportions fluctuated, with 12 statistically significant changes (6 up, 6 down). The reduction of ST-11 complex serogroup C meningococci was
BACKGROUND: Herd immunity is important in the effectiveness of conjugate polysaccharide vaccines against encapsulated bacteria. A large multicenter study investigated the effect of meningococcal serogroup C conjugate vaccine introduction on the meningococcal population. METHODS: Carried meningococci in individuals aged 15-19 years attending education establishments were investigated before and for 2 years after vaccine introduction. Isolates were characterized by multilocus sequence typing, serogroup, and capsular region genotype and changes in phenotypes and genotypes assessed. RESULTS: A total of 8462 meningococci were isolated from 47 765 participants (17.7%). Serogroup prevalence was similar over the 3 years, except for decreases of 80% for serogroup C and 40% for serogroup 29E. Clonal complexes were associated with particular serogroups and their relative proportions fluctuated, with 12 statistically significant changes (6 up, 6 down). The reduction of ST-11 complex serogroup C meningococci was
Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, a French pharmaceutical group, has announced that it is the first international vaccine company to enter the Japanese pediatric vaccine market with ActHIB vaccine. Sanofi Pasteurs ActHIB vaccine (Haemophilus influenzae type b conjugate vaccine) is marketed in Japan by Daiichi-Sankyo Co and will be available starting December 19, 2008. Wayne Pisano, president and CEO of Sanofi Pasteur, said: Sanofi Pasteur is proud to help protect Japanese children against bacterial meningitis and improve public health in the country. Being the first to enter the Japanese pediatric vaccine market is an achievement that underlines Sanofi Pasteurs strength and commitment to provide the highest quality innovative vaccines.. ...
BACKGROUND: Neisseria meningitidis serogroup A is the main causative pathogen of meningitis epidemics in sub-Saharan Africa. In recent years, serogroup W135 has also been the cause of epidemics. Mass vaccination campaigns with polysaccharide vaccines are key elements in controlling these epidemics. Facing global vaccine shortage, we explored the use of fractional doses of a licensed A/C/Y/W135 polysaccharide meningococcal vaccine. METHODS AND FINDINGS: We conducted a randomized, non-inferiority trial in 750 healthy volunteers 2-19 years old in Mbarara, Uganda, to compare the immune response of the full dose of the vaccine versus fractional doses (1/5 or 1/10). Safety and tolerability data were collected for all subjects during the 4 weeks following the injection. Pre- and post-vaccination sera were analyzed by measuring serum bactericidal activity (SBA) with baby rabbit complement. A responder was defined as a subject with a ,/=4-fold increase in SBA against a target strain from each serogroup ...
Make an impact. Sanofi Pasteur is the largest company entirely dedicated to vaccines. 군포시장애인종합복지관 (부설: 군포시장애인스포츠육성센터) 김용철 경기도 군포시 청백리길 18 군포시장애인종합복지관 (부설:군포시장애인스포츠육성센터). 17 Sanofi Pasteur jobs available in Swiftwater, PA on Indeed. Title: Full page photo Author: nm55010 Created Date: 1/21/2019 11:38:12 AM. Head lice infect an estimated 6 to 12 million children aged 3 to 11 years annually, according to the US Centers for Disease Control and Prevention. Glassdoor has 3,971 Sanofi reviews submitted anonymously by Sanofi employees. For more information, please visit: www. Krile b John A. Dunn a Thomas Brundage a Jody M. Video-As Sanofi plans 70M flu shots in U. The Food and Drug Administration (FDA) has approved the expanded use of Fluzone Quadrivalent (influenza vaccine; Sanofi Pasteur) 0. Please note that this form is not to be used to report health concerns or to ask ...
Background Recently the incidence of meningococcal serogroup Y (MenY) and in particular serogroup W (MenW) invasive disease has risen in several European countries, including the Netherlands. Adolescents are a target group for primary prevention through vaccination to protect against disease and reduce carriage and induce herd protection in the population. ... read more The present study assessed MenA, MenW and MenY antibody levels in adolescents up to one year following primary vaccination with quadrivalent MenACWY-PS conjugated to tetanus toxoid (MenACWY-TT). Methods In this phase IV, open-label study, healthy 10-, 12- and 15-year-olds received the MenACWY-TT vaccine. Blood samples were collected before, 1 month and 1 year after the vaccination. Functional antibody levels against MenA, MenW and MenY were measured with serum bactericidal assay using baby rabbit complement (rSBA). MenA-, MenW-, and MenY-PS specific IgG, IgG1 and IgG2 levels were measured using fluorescent-bead-based multiplex ...
Dr. Larry Lutwick answered: Conjugate in theory: Conjugating the Meningococcal capsule polysaccharide to a protein backbone ma...
BACKGROUND: Neisseria meningitidis is a globally important cause of meningitis and septicaemia. Twelve capsular groups of meningococci are known, and quadrivalent vaccines against four of these (A, C, W and Y) are available as plain-polysaccharide and protein-polysaccharide conjugate vaccines. Here we apply contemporary methods to describe B-cell responses to meningococcal polysaccharide and conjugate vaccines. METHODS: Twenty adults were randomly assigned to receive either a meningococcal plain-polysaccharide or conjugate vaccine; one month later all received the conjugate vaccine. Blood samples were taken pre-vaccination and 7, 21 and 28 days after vaccination; B-cell responses were assessed by ELISpot, serum bactericidal assay, flow cytometry and gene expression microarray. RESULTS: Seven days after an initial dose of either vaccine, a gene expression signature characteristic of plasmablasts was detectable. The frequency of newly generated plasma cells (CXCR3(+)HLA-DR(+)) and the expression of
Sanofi Pasteur, the vaccines division of Sanofi, announced a long-term strategic cooperation with SK Chemical Co. to co-develop an innovative pneumococcal conjugate vaccine (PCV). This agreement will enable Sanofi Pasteur to access the global PCV market of $4 billion USD. The World Health Organisation (WHO) recommends the use of PCVs in all countries. The collaboration…
Increase in outbreaks of meningococcal disease and surge in immunization programs across the globe drive the growth of the global meningococcal vaccines
CONTEXT: The success of conjugate vaccines in decreasing invasive disease due to Streptococcus pneumoniae and group C Neisseria meningitidis has placed pressure on crowded infant immunization schedules, making development of combination vaccines a priority. OBJECTIVE: To determine the safety and immunogenicity of a combination 9-valent pneumococcal-group C meningococcal conjugate candidate vaccine (Pnc9-MenC) administered as part of the routine UK infant immunization schedule at ages 2, 3, and 4 months. DESIGN, SETTING, AND PARTICIPANTS: Phase 2 randomized controlled trial conducted from August 2000 to January 2002 and enrolling 240 healthy infants aged 7 to 11 weeks from 2 UK centers, with home follow-up visits at ages 2, 3, 4, and 5 months. INTERVENTION: Pnc9-MenC (n = 120) or monovalent group C meningococcal conjugate vaccine (MenC) (n = 120) administered in addition to routine immunizations (diphtheria and tetanus toxoids and whole-cell pertussis [DTwP], Haemophilus influenzae type b [Hib]
OBJECTIVES: This study evaluated the immune response and safety profile of 13-valent pneumococcal conjugate vaccine (PCV13) in preterm infants compared with term infants. METHODS: This Phase IV, open-label, 2-arm, multicenter, parallel-group study enrolled 200 healthy infants (preterm, n = 100; term, n = 100) aged 42 to 98 days. All subjects received PCV13 at ages 2, 3, 4 (infant series), and 12 (toddler dose [TD]) months, together with routine vaccines (diphtheria-tetanus-acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b vaccine and meningococcal group C conjugate vaccine). RESULTS: Most subjects achieved an anticapsular immunoglobulin G (IgG) antibody concentration ≥ 0.35 µg/mL for all serotypes: >85% after the infant series (except preterm infants for serotypes 5, 6A, and 6B) and >97% after TD (except for serotype 3). Preterm infants had overall lower IgG geometric mean concentrations compared with term infants; however, geometric mean fold ...
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitidis.[1] Different versions are effective against some or all of the following types of meningococcus: A, C, W-135, and Y.[1] The vaccines are between 85 and 100% effective for at least two years.[1] They result in a decrease in meningitis and sepsis among populations where they are widely used.[2][3] They are given either by injection into a muscle or just under the skin.[1]
The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in the Brazilian National Immunization Program in March 2010, scheduled at 2, 4, and 6 months, with a booster at 12-15 months of age. The meningococcal C conjugate vaccine (MCC) was introduced in November 2010, scheduled at 3 and 5 months, with a booster dose at 12-15 months of age and no catch-up for older age groups. In this interrupted time-series analysis study, we used Brazilian mortality data from 2005 to 2015 for children under five years of age (excluding data from the state of Bahia) to assess the combined impact of these vaccines on the overall burden of meningitis mortality among children aged 0-23 months and 2-4 years, as defined using meningitis and meningococcemia specific International Classification of Diseases - tenth revision codes ...
NPO Microgen, part of the National Immunobiological Company, has begun Phase I clinical trials of the first Russian polysaccharide meningococcal vaccine against serotypes A and C.
Although recommended for college students, the meningococcal vaccine is also recommended for all young people and individuals with certain medical conditions.
Lyon, France and Rio de Janeiro, Brazil - October 29, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today a partnership with the Bill & Melinda Gates Foundation to explore and develop new platforms and methods intended to accelerate vaccine R&D, particularly in areas of global health. The announcement was made at the Grand Challenges in Global Health meeting in Rio de Janeiro, Brazil during a session focused on affordable technologies for the developing world. The conference initiated by the Gates Foundation was first held in 2003 to focus on persistent challenges in improving health and development in poor countries.. The Vaccine Discovery Partnership (VxDP) is a newly created, formal mechanism by which the Gates Foundation can directly collaborate with Sanofi Pasteur and other vaccine-pharmaceutical companies across disease areas of interest. It provides an integrated, straight-forward and sustained relationship based on a memorandum of ...
Between December 1991 and March 1992 we allocated 158 volunteers by block permuted randomisation to receive 0.5 ml typhoid polysaccharide vaccine (Typhim Vi, Merieux) intramuscularly (group A); 0.5 ml meningococcal polysaccharide vaccine (Mengivac (A+C), Merieux) intramuscularly (group B); or a mixture of both vaccines, the liquid typhoid vaccine being used to reconstitute the lyophilised meningococcal vaccine (group C). Group A comprised 54 subjects (27 men and women, median age 23 (range 18-56)), group B 50 (21 men, 29 women, median age 21 (18-62)), and group C 54 (24 men, 30 women, median age 22 (18-54)). Exclusion criteria were pregnancy, compromised immune system, fever, receiving any vaccine or immunoglobulin in the preceding three months, typhoid vaccination within the previous three years, previous meningococcal vaccination, and a history of typhoid or meningococcal disease. Volunteers kept a diary for five days recording pain in their arm (0=no pain, 1=pain on pressure, 2=pain on ...
Dr. Ta has over 15 years of experience in the life sciences sector, including more than 12 years of vaccine R&D, commercial and policy experience. Dr. Ta started with Sanofi Pasteur in 2004 as a scientist and supported the development of innovative vaccines before transitioning to commercial operations in 2010. Prior to his current role, Dr. Ta led the marketing team, directed the strategic planning process, and supported communications activities for Sanofi Pasteur in Canada ...
Welcome to sanofi pasteur, Sanofi Pasteur, the vaccines division of sanofi-aventis Group, is the largest company in the world devoted entirely to human vaccines.
A phase II clinical study was conducted in African toddlers (aged 12 to 23 months), with subjects receiving either investigational meningococcal group A conjugate (PsA-TT), meningococcal ACWY polysaccharide (PsACWY), or Haemophilus influenzae type b (Hib-TT) vaccine. Ten months following vaccination, the 3 study groups were further randomized to receive a dose of PsA-TT, a 1/5 dose of PsACWY, or a dose of Hib-TT vaccine. Group A serum bactericidal antibody (SBA) results have been reported previously, with PsA-TT demonstrating superior immunogenicity versus PsACWY vaccine. Immunogenicity for serogroups W135 and C was assessed by SBA assay to investigate the impact of multiple doses in this age group. Blood samples were taken prior to vaccination, 28 days and 40 weeks post-primary vaccination, and 7 and 28 days post-booster vaccination with a 1/5 dose of PsACWY. Subjects who had previously received a full dose of PsACWY had W135 SBA geometric mean titers (GMTs) of 26.1 and 4.4 at 7 and 28 days ...
Researchers have now developed a new vaccine, a native outer membrane vesicle (NOMV) vaccine, for meningitis and bloodstream infections caused by meningococcal group B bacteria. This will allow younger people to be vaccinated and will address several limitations of the current vaccinations. The research is published this week in mBio, a journal of the American Society for Microbiology.. We developed the improved version of the vaccine by making several genetic changes to the strain of bacteria used to produce the vaccine, resulting in a broadly protective vaccine rather than a strain-specific vaccine, said Peter Beernink, Ph.D., Scientist at the Center for Immunobiology and Vaccine Development, Benioff Childrens Hospital Oakland.. There are currently only two licensed vaccines for prevention of meningitis and bloodstream infections caused by meningococcal group B bacteria, which are only licensed for use in people age 10 years and older. Both vaccines contain a bacterial protein known as ...
Strains belonging to capsular serogroup A N. meningitidis (MenA) have been the main cause of the devastating epidemics of meningitis occurring in sub-Saharan Africa, but there has been an increasing contribution of serogroups W and X strains with epidemic potential in the last two decades.. Protein-conjugated polysaccharide vaccines against serogroup A, C, W and Y meningococcal disease have been developed for the Western market, but the price of these products is prohibitive to their use by developing countries. To-date there is no commercial vaccine against MenX.. Through a public-private partnership between the World Health Organization (WHO) and the Program for Appropriate Technology in Health (PATH), an affordable polysaccharide conjugate vaccine (MenAfriVac) has been developed for preventive mass immunization against MenA in the meningitis belt. The vaccine was introduced in mass vaccination campaigns starting in 2010 and to-date more than 200 million individuals between 1 and 29 years of ...
As a member of the wwPDB, the RCSB PDB curates and annotates PDB data according to agreed upon standards. The RCSB PDB also provides a variety of tools and resources. Users can perform simple and advanced searches based on annotations relating to sequence, structure and function. These molecules are visualized, downloaded, and analyzed by users who range from students to specialized scientists.
The 4CMenB vaccine was licensed for use in Europe in January 2013, with approved dosage schedules including the 2, 4, 6, 12 month and 40, 42 month schedules evaluated in this study. In contrast to the single dose of 4CMenB given at 12 months of age to one of our study groups, the licensed indication for children 1-2 years of age is 2 doses of 4CMenB at least 2 months apart, with a booster dose given 1-2 years later.. Among children who received 4CMenB at 2, 4, 6, and 12 months of age in the original study, by 40 months of age the proportions with hSBA titres of 1:4 or greater were 65% for strain 44/76-SL (fHbp), 76% for strain 5/99 (NadA) and 41% for strain NZ98/254. These proportions represent a decline from 13 months of age (100%, 93% and 96%, respectively).3 However, a good response to a booster dose of vaccine was observed. Experience with other meningococcal vaccines has shown that waning of bactericidal antibody titres was associated with a decline in vaccine effectiveness following infant ...
Background: In a previous study, 60 infants receiving an investigational serogroup B meningococcal vaccine containing recombinant meningococcal proteins alone (rMenB) or combined with an outer membrane vesicle from Neisseria meningitidis (4CMenB) at 6, 8 and 12 months of age produced serum bactericidal antibodies (SBAs) against meningococcal strains expressing vaccine antigens. We studied persistence of this response and the response to a booster dose of vaccine. Methods: In this extension study, SBA titers were evaluated before and after a booster dose of rMenB or 4CMenB at 40 months of age. MenB vaccine naïve age-matched children served as a control group. Results: Before the booster doses, the proportions of 4CMenB recipients with SBA titers ≥1:4 were 36% (n = 14, 95% confidence interval: 13-65%) for strain 44/76-SL, 100% (77-100%) for 5/99, 14% (2-43%) for NZ98/254 and 79% (49-95%) for M10713. These percentages were 14% to 29% for rMenB recipients (n = 14), except for 5/99 (93%, 66-100%). For
What is meningococcal disease and what are the complications of this disease? Invasive meningococcal disease is caused by a bacteria called Neisseria meningitidis (N. meningitidis). There are many different groups or types of this bacteria that can cause disease. Each type is identified by a letter. The bacteria can cause infection of joints (septic arthritis), blood
Learn CC Sept 2015 Serogroup B Meningococcal Vaccine facts using a simple interactive process (flashcard, matching, or multiple choice). Finally a format that helps you memorize and understand. Browse or search in thousands of pages or create your own page using a simple wizard. No signup required!
Understanding predisposing factors for meningococcal carriage may identify targets for public health interventions. Before mass vaccination with meningococcal group C conjugate vaccine began in autumn 1999, we took pharyngeal swabs from ≈14,000 UK teenagers and collected information on potential risk factors. Neisseria meningitidis was cultured from 2,319 (16.7%) of 13,919 swabs. In multivariable analysis, attendance at pubs/clubs, intimate kissing, and cigarette smoking were each independently and strongly associated with increased risk for meningococcal carriage (p&lt;0.001). Carriage in those with none of these risk factors was 7.8%, compared to 32.8% in those with all 3. Passive smoking was also linked to higher risk for carriage, but age, sex, social deprivation, home crowding, or school characteristics had little or no effect. Social behavior, rather than age or sex, can explain the higher frequency of meningococcal carriage among teenagers. A ban on smoking in public places may reduce risk
The stability during storage of outer membrane vesicles (OMVs) of Neisseria meningitidis group B was studied. Three types of OMVs were compared for their stability, containing either one (monovalent) or three different PorA subtypes (trivalent), the latter with and without class 4 outer membrane protein (OMO, RmpM).Aqueous formulations were stored freeze-dried (4 degreesC), frozen (-70 degreesC) and in liquid form at 4, 37 and 56 degreesC. Physico-chemical properties and immunogenicity of the OMVs as well as PorA conformation and antigenicity (P1.7-2,4, the subtype present in all formulations) were monitored during 1 year. At -70 or 4 degreesC, the structure and immunogenicity of OMVs was preserved. Storage of OMVs at high temperatures (37 or 56degreesC) induced destruction of the OMV structure and denaturation of PorA, followed by chemical degradation. Immunogenicity decreased or was lost completely. Changes observed in the fluorescence spectra of degraded OMVs were also seen in tryptophan ...
Invasive Meningococcal Disase (IMD) is an important cause of death and disability for which teenagers and young adults are at particular risk. IMD mortality is approximately 10%. Of IMD survivors 10-20% have long term sequelae including hearing loss, neurologic disabilities and digit or limb amputations . In Canada, IMD is caused by the two most prominent strains - B and C strains. Other vaccine preventable strains are A, W and Y strains. Meningococcal ACWY (Menactra/Menveo) is given to Ontario teenagers at no cost in grade 7. We also encourage a booster of Meningococcal ACWY in grade 12. Meningococcal B vaccine (Bexsero) Is recomenneded to prevent IMD caused by B strain which is the most common strain leading to IMD in Canada. We encourage immunization against Meningococcal B strain to all teenagers age 15 and older. It is not currently paid for by OHIP and is available for private purchase in our office. Please call our office to book an appointment to recieve Meningococcal B vaccine. -return ...
Physician reviewed meningococcal group B vaccine patient information - includes meningococcal group B vaccine description, dosage and directions.
Meningococcal Vaccination. Meningococcal disease, which is any type of illness caused by the Neisseria meningitidis bacteria, is spread by direct contact with infected people by coughing, kissing, or sharing anything by mouth, like utensils or toothbrushes. It can cause pneumonia, blood stream infection, and meningitis (swelling of the covering of the brain and spinal cord which can be fatal). Severe disease can cause brain damage, hearing loss, or limb loss. People exposed to the meningococcal bacteria may experience fever, cough, runny nose, headache, neck stiffness, nausea/vomiting, sensitivity to light and/or confusion.. Meningococcal vaccine can prevent four types of meningococcal disease. It cant prevent all types of the disease, but it does help protect many people who might become sick if they dont get the vaccine. Two meningococcal vaccines are available in the US.. ...
Find information on Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra, Menveo) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
Meningococcal disease is a serious illness caused by a type of bacteria called Neisseria meningitidis. It can lead to meningitis (infection of the lining of the brain and spinal cord) and infections of the blood. Meningococcal disease often occurs without warning - even among people who are otherwise healthy. Meningococcal disease can spread from person to person through close contact (coughing or kissing) or lengthy contact, especially among people living in the same household.. There are at least 12 types of N. meningitidis, called serogroups. Serogroups A, B, C, W, and Y cause most meningococcal disease. CDC recommends vaccination with a meningococcal conjugate vaccine for all preteens and teens at 11 to 12 years old, with a booster dose at 16 years old. Teens and young adults (16 through 23 year olds) also may be vaccinated with a serogroup B meningococcal vaccine.. The Meningococcal B vaccine became a topic of conversation in the fall of 2016 when the UW-Madison college campus reported an ...
The first safe and effective vaccine for the prevention of invasive meningococcal disease was created fifty years ago. The vaccine employed a novel platform, polysaccharide capsular antigen, based on the discovery that anticapsular antibody conferred protective immunity in humans. As with most new paradigms in vaccinology, it derived from important basic research from other scientific disciplines over the preceding years. The success of the first monovalent polysaccharide vaccine in nearly eliminating invasive meningococcal disease in military settings led to accelerated advances in polysaccharide vaccine development against other serogroups of meningococcus and other encapsulated pathogens. As gaps in vaccine efficacy arose over the past half-century, new vaccine technologies and approaches were developed to address the challenges. Several of these, including conjugate vaccines and reverse vaccinology led to other novel, successful vaccines that have had a significant, favorable global impact on
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
with disappointing results. A total of 240 infants were given Pnc9-MenC or monovalent group C meningococcal conjugate vaccine (MenC) at 2, 3, and 4 months in addition to other routine immunisations. The MenC component of the combined vaccine was less immunogenic than monovalent MenC vaccine, giving a lower mean serum bactericidal titre and with a titre of ,1:8 achieved by 95% (Pnc9-MenC) vs 100% (MenC). Antibody responses to Hib and diphtheria vaccines given at the same time were also less in the Pnc9-MenC group. All nine pneumococcal serotype components of the combined vaccine were immunogenic. Irritability and reduced activity were more common after Pnc9-MenC than after MenC. These researchers conclude that the combined vaccine tested may not be an adequate replacement for current separate pneumococcal and meningococcal vaccines.. Two disease-modifying drugs, methotrexate and leflunomide, have been compared for the treatment of polyarticular juvenile idiopathic arthritis ( ...
It is now 5 years since the UK became the first country to introduce the serogroup C meningococcal polysaccharide-protein conjugate vaccines (MenC) into its routine immunisation schedule. This article reviews the global use of MenC with particular reference to the range of immunisation strategies used internationally. To date, concerns that MenC may result in an increase in meningococcal disease due to non-C serogroups have not been realised. The vaccine has proved to be highly safe and effective; however, concerns have arisen regarding the duration of vaccine effectiveness. Although booster doses of MenC may potentially extend the duration of protection offered by the vaccine, there are, as yet, no studies assessing this option. Clinical trials are underway to assess new combination conjugate vaccines (containing A, C, Y, and W polysaccharides), and it is probable that these more broadly protective vaccines will become available in the near future.
Well, the Internet is making an impact on the lives of many Canadians in ways that we never imagined even ten years ago. You are coming with a question after you read some information on the Internet. It is an interesting and important question. I will try to give you an answer that hopefully will help you to make the right decision.. Meningococcal vaccine protects a person against the bacteria Neisseria meningitidis (also called meningococcus). There are 13 recognized groups of meningococcus. The most common ones that cause infection are A, B, C, Y, and W-135. Interesting enough, humans are the only ones susceptible to meningococcus.. About 10-30% of healthy teenagers and adults carry meningococcus in their throat. It is spread from person to person through droplets from the respiratory tract. That is why these bacteria spread more easily in crowded situations and when people share drinking or eating utensils. However, it is not clear why some carry the bacteria and stay healthy, while others ...
Rekomendasi Imunisasi Meningococcal Conjugate Vaccine (MCV) Rekomendasi terbaru vaksin meningokokus telah dikeluarkan oleh American Association of Pediatrics, komite AAP bagian penyakit menular dan Advisory Committee on Immunization Practices dari Centers for Disease Control and Prevention (CDC). Rekomendasi terbaru tersebut menyarankan pemberian sejak usia 9 bulan pada kelompok resiko tinggi dengan pemberian vaksinasi MCV4. Rekomendasi tsebelumnya juga menyarankan…
New York City health officials recommend the meningococcal vaccine to HIV-infected male city residents who have had intimate contact with any man met online.
Global Meningococcal Vaccines Sales Market Report 2017 is a market research report available at US $4000 for a Single User PDF License from RnR Market Research Reports Library.
At IDWeek 2012, study researchers presented data showing that MenACWY-CRM, a quadrivalent meningococcal conjugate vaccine, has been shown to be highly immunogenic and well tolerated across age groups.
The meningococcal group B vaccines include little blebs of bacterial membrane from the outside of the bacterial cell wall. These structures, known as Outer Membrane Vesicles (OMV), are purified from the bacteria and used as vaccine antigens.. OMVs include a range of immunogenic proteins. Some are well characterised, others less so, which means there are many angles to explore. The focus to date has been on those most pertinent for protection against meningococcal disease, but those that may be of interest to gonorrhoea have yet to be more comprehensively considered.. MeNZB was developed to control a meningococcal disease epidemic and is no longer available, but the OMV antigens in that vaccine have been included in the more recently developed 4CMenB vaccine (Bexsero), which is available in many countries, including Australia. In addition, the Cuban vaccine, which was associated with a drop in gonorrhoea in that country, has been used widely and is still available.. At the moment, the specific ...
Learn about the 2-dose schedule option for patients prescribed Trumenba® (Meningococcal Group B Vaccine). See risks and benefits of Trumenba.
Learn about the 2-dose schedule option for patients prescribed Trumenba® (Meningococcal Group B Vaccine). See risks and benefits of Trumenba.
Find information on Meningococcal Group B Vaccine (Bexsero, Trumenba) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
This is a reminder that if your senior student has not had their 2nd meningococcal conjugate vaccine, they are currently on a 60 day provisional certificate from the date of registration. After October 15, they will be excluded from school until proof of vaccine is received. Phone calls have been made and letters have been mailed to identified students parents. Please make the appointment as soon as possible and have your senior bring proof of immunization to the health office. Any questions may be directed to the health office at 712-366-8272. ...
A new Illinois law requires any student considered a senior at LPHS to show proof of having had two doses of a meningococcal conjugate vaccine. If the first dose was given after age sixteen only one ...
Meningococcal ACWY (Menactra/Menveo) is given to Ontario teenagers at no cost in grade 7 . Invasive Meningococcal Disease (IMD) is an important cause of sudden onset bacterial blood infections (Septicemia) leading to Meningitis , disability and death. IMD mortality is approximately 10%. Of IMD survivors 10-20% have long term sequelae including hearing loss, neurologic disabilities and digit or limb amputations Teenagers and young adults are high risk age groups for this bacterial infection. The Centre for Disease control recommends a dose of Menactra/Menveo to be given in Grade 7 and a booster dose in Grade 12 to boost immunity post secondary school . We agree and recommend a second dose of Menactra/Menveo as a booster in Grade 12. It is not covered by OHIP and is available for a fee at our office. Please call our office and book an appointment to recieve a Meningococcal ACWY (Menactra/Menveo) booster.. -return to Vaccination for teenagers - our recommendations-. ...
Sanofi Pasteur (sanofi-aventis) is developing a subunit vaccine against meningococcal B (Neisseria meningitidis serotype B) infections. This vaccine is being
OBJECTIVE: To study the immunogenicity and reactogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (Hib-MenC-TT) when administered as a booster dose in combination with a measles, mumps and rubella vaccine (MMR). DESIGN: A phase 3 open randomised controlled trial. SETTING: One centre in Oxford, UK and nine centres in Poland. SUBJECTS: 12-15-month-old healthy children. INTERVENTIONS: In the primary stage of the study 500 healthy 6-12-week-old infants were randomised in a 3:1 ratio to receive Hib-MenC-TT+DTPa-IPV or MenC-CRM197 vaccine+DTPa-IPV-Hib. In the booster stage, 476 participants (190 in the UK and 286 in Poland) were vaccinated with Hib-MenC-TT and MMR. MAIN OUTCOME MEASURES: The proportion of children with protective serum antibody levels against MenC and Hib 6 weeks following a Hib-MenC-TT booster dose. RESULTS: The co-primary objectives were met: the Hib-MenC-TT booster dose induced protective antibody titres in
Meningococcal disease is a life-threatening illness caused by bacteria that infect the bloodstream (sepsis) and the lining that surrounds the brain and spinal cord (meningitis). Neisseria meningitidis is a leading cause of meningitis in young children. Even with appropriate antibiotics and intensive care, between 10 percent and 15 percent of people who develop meningococcal disease die from the infection. Another 10 percent to 20 percent suffer complications such as brain damage or loss of limb or hearing ...
How does IMD present?. The clinical presentation of IMD is non-specific with features including sudden-onset fever, a rash (which may be petechial, purpuric or maculopapular); altered LOC, cool peripheries, nausea and vomiting; and photophobia and neck stiffness (with meningitis). The mortality risk is high (between 5 to 10% even with appropriate antibiotic therapy), and of those who survive up to 1 in 3 will suffer long-term consequences (predominantly limb deformities, sensorineural hearing loss and neurological deficits). This high mortality and morbidity burden is secondary to endotoxin-induced vascular collapse induced by N.menigitidis.. Recent resurgences: Despite media reports often marred by an element of hysteria, IMD remains extremely rare with 1.1 per 100,000 people diagnosed in Australia in 2016[5] (compare this to the incidence of influenza which occurs in close to 500 per 100,000 Australian children each season, necessitating ICU admission in 6 per 100,000).[6] IMD has seasonal and ...
The purpose of this study is to assess the impact of campaign in preventing invasive meningococcal disease among vaccinees and to reduce B-IMD incidence in the
The National Foundation for Infectious Diseases (NFID) S.T.O.P. (Share. Teach. Outreach. Protect.) Meningitis! coalition, composed of many of the nations leading medical and advocacy organizations, recently issued a Call to Action to improve adolescent meningococcal vaccination rates and to reduce immunization disparities among racial and ethnic groups and other underserved populations.. Meningococcal disease is a serious bacterial infection that progresses rapidly and often leads to death or long-term health consequences, said Susan J. Rehm, MD, NFID Medical Director and Vice Chair, Department of Infectious Disease at the Cleveland Clinic. To ensure adolescents across all racial, ethnic, and socioeconomic groups are protected from this devastating disease, increased efforts are needed to reduce disparities and educate families about the benefits of meningococcal vaccination.. The Centers for Disease Control and Prevention (CDC) recommends meningococcal vaccination for all adolescents ...
Poliomyelitis, Sanofi Pasteur, the vaccines division of Sanofi, is the largest company in the world devoted entirely to human vaccines.
Two University of Massachusetts Amherst students hospitalized to treat a potentially deadly meningococcal disease have a strain of the illness students are generally not vaccinated for. We have received confirmation that the diagnosis for the second student is Serogroup B. This is a confirmation that UHS had anticipated, University Health Services Executive Director George Corey said in an email to campus on Wednesday. UHS continues to work in consultation with federal and state public
Two University of Massachusetts Amherst students hospitalized to treat a potentially deadly meningococcal disease have a strain of the illness students are generally not vaccinated for. We have received confirmation that the diagnosis for the second student is Serogroup B. This is a confirmation that UHS had anticipated, University Health Services Executive Director George Corey said in an email to campus on Wednesday. UHS continues to work in consultation with federal and state public
Two University of Massachusetts Amherst students hospitalized to treat a potentially deadly meningococcal disease have a strain of the illness students are generally not vaccinated for. We have received confirmation that the diagnosis for the second student is Serogroup B. This is a confirmation that UHS had anticipated, University Health Services Executive Director George Corey said in an email to campus on Wednesday. UHS continues to work in consultation with federal and state public
Two University of Massachusetts Amherst students hospitalized to treat a potentially deadly meningococcal disease have a strain of the illness students are generally not vaccinated for. We have received confirmation that the diagnosis for the second student is Serogroup B. This is a confirmation that UHS had anticipated, University Health Services Executive Director George Corey said in an email to campus on Wednesday. UHS continues to work in consultation with federal and state public
Early symptoms can be similar to the flu or other viral infections, often leading to a misdiagnosis. But symptoms can progress very quickly, killing an otherwise healthy young adult within hours. Its important to recognize the symptoms so that medical attention can be sought immediately.. Vaccination offers the best protection against meningococcal disease. You can get the bacteria that causes meningococcal disease from someone who has no symptoms or whose symptoms may appear mild.. Meningococcal vaccine recommendations for MSM. The Centers for Disease Control and Prevention recommends meningococcal vaccination to control outbreaks, such as those in Chicago and New York City. State and local public health departments may make additional recommendations based on local needs.. ...
Lyon, France (ots/PRNewswire) - - Six Million Doses of Stamaril(TM) Vaccine Shipped in Record Time to Brazil and Paraguay Sanofi Pasteur, the vaccines division of the...
... the meningococcal vaccine, does not cause Guillain-Barré Syndrome. ... Where can I get more information about meningococcal vaccine?. More information is available on CDCs Meningococcal Vaccination ... How can I report a case of GBS after Menactra or any vaccine?. Any possible vaccine side effect can be reported to the Vaccine ... Vaccine Safety Monitoringplus icon *Vaccine Adverse Event Reporting System (VAERS)plus icon *How to Access Data from CDCs ...
meningococcal B vaccines available. The same information.. vaccine must be used for all doses.. Meningococcal B vaccines are ... meningococcal B vaccine.. For best protection, more than 1 dose of a meningococcal B vaccine is needed. There are two Your ... Meningococcal B vaccine can help protect against deficiency". meningococcal disease caused by serogroup B. A Anyone taking a ... Vaccine Information Statement (Interim). Meningococcal B Vaccine. Office use only. 8/15/2019 , 42 U.S.C. § 300aa-26. ...
It can be prevented with the meningococcal vaccines. ... Meningococcal disease is caused by a bacteria than can lead to ... Who gets meningococcal disease?. The meningococcal vaccine helps prevent the meningococcal disease caused by a bacterium called ... Meningococcal vaccines. by Jennifer Weatherhead Sep 23, 2009 at 12:10 pm EDT ... Mild side effects of the meningococcal vaccines include redness and soreness around the injection area and, in some cases, a ...
doi: 10.1016/j.vaccine.2009.05.003. Epub 2009 May 27. Research Support, Non-U.S. Govt; Review ... doi: 10.1016/j.vaccine.2009.05.003. Epub 2009 May 27.. Quadrivalent meningococcal conjugate vaccines.. Pace D1, Pollard AJ, ... This vaccine and others in development offer the potential to broaden population protection against meningococcal disease. ... vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal ...
Vaccine, meningococcal: A vaccine to prevent meningococcal meningitis, an inflammation of the membranes that cover the brain ...
... the meningococcal vaccine is also recommended for all young people and individuals with certain medical conditions. ... The vaccines are MenACWY (meningococcal conjugate vaccine) and MPSV4 (meningococcal polysaccharide vaccine). ... Types of vaccines. This vaccine is offered in two versions in the United States. Both vaccines are quadrivalent. This means ... The meningococcal vaccine is recommended for young adults who will be living in shared spaces. Its also recommended to the ...
About Meningococcal vaccine: ---------------------------------------------------. Vaccine in India is already in use. One of ... This is a form to show your interest in participating in the Meningococcal Vaccine (ACWYX) clinical trial (PI: Dr. Sandeep ... About Meningococcal vaccine trial (ACYWX): ---------------------------------------------------. Trial is expected to start from ... About Meningococcal meningitis: ---------------------------------------------------. Meningococcal meningitis is a bacterial ...
Meningococcal ACWY Vaccines (MenACWY): learn about side effects, dosage, special precautions, and more on MedlinePlus ... Mild problems following meningococcal vaccination:. *As many as half the people who get meningococcal ACWY vaccine have mild ... Meningococcal ACWY vaccines can help prevent meningococcal disease caused by serogroups A, C, W, and Y. A different ... If you have ever had a life-threatening allergic reactionafter a previous dose of meningococcal ACWY vaccine, or if you have a ...
Find out when and why your child needs to get this vaccine. ... and vaccine brand. Some types of meningococcal vaccines can be ... Two kinds of meningococcal (meh-nin-guh-KOK-uhl) vaccines are currently given to kids in the United States:. *The meningococcal ... The meningococcal B vaccine (MenB) protects against a fifth type of meningococcal bacterium (called type B). It is fairly new ... Why Are Meningococcal Vaccines Recommended?. Meningococcal disease is caused by a type of bacteria. It can lead to an infection ...
Learn why experts recommend that kids get the meningococcal vaccine at age 11 or 12 and a booster at age 16 to prevent ... This vaccine protects against the bacteria Neisseria meningitidis, which causes meningococcal disease. Before the vaccine, ... Who shouldnt get the meningococcal vaccine?. A child who has had a life-threatening allergic reaction to a previous dose of ... The vaccine protects against most types of meningococcal disease, but it doesnt prevent all cases. ...
More than one-third of students vaccinated with meningococcal vaccine showed no response to the shot, raising serious questions ... More than one-third of students vaccinated with meningococcal vaccine showed no response to the shot, raising serious questions ... Strain B, another type not included in the four-strain vaccine, is associated with more than 50 percent of meningococcal cases ... In 2016, the U.S. Food and Drug Administration (FDA) licensed a meningococcal vaccine including strain B ...
The American Academy of Pediatrics now recommends that 16-year-olds receive a booster dose of the meningococcal conjugate ... Available quadrivalent meningococcal conjugate vaccines, which protect against serogroups A, C, W-135, and Y, are Menactra ( ... December 7, 2011 - Adolescents should be routinely immunized with the quadrivalent meningococcal conjugate vaccine (MCV4) at 11 ... Cite this: AAP Updates Meningococcal Vaccine/Booster Dose Guidelines - Medscape - Dec 07, 2011. ...
... life-threatening allergic reaction to a meningococcal vaccine before or to any vaccine component *is moderately ... your preteen or teen shouldnt get the meningococcal vaccine if he: *has had a severe, ... More Answers On Vaccines. *What are serious side effects of meningococcal vaccines? ... Have had a severe, life-threatening allergic reaction to a meningococcal vaccine before or to any vaccine component ...
Proper Name: Haemophilus B Conjugate Vaccine (Meningococcal Protein Conjugate) Tradename: Liquid PedvaxHIB. Manufacturer: Merck ...
Whereas, Two meningococcal conjugate vaccines (MCV4) are licensed in the United States and approved for persons age 2-55; and ... Whereas, Meningococcal disease is often misdiagnosed as something less ser ious because early symptoms are similar to the flu, ... Whereas, Meningococcal disease is a serious, potentially fatal bacterial infection that strikes between 1,000 to 3,000 ... Whereas, Meningococcal disease is contagious, spread through air droplets and direct contact with secretions of infected ...
... Size And Forecast Meningococcal Vaccines Market was valued at USD 3.5 Billion in 2018 and is ... Global Meningococcal Vaccines Market Outlook The rising incidence of meningitis across the world has be ... Meningococcal Vaccines Market Size And Forecast. Meningococcal Vaccines Market was valued at USD 3.5 Billion in 2018 and is ... Global Meningococcal Vaccines Market Competitive Landscape. The Global Meningococcal Vaccines Market study report will provide ...
Recommendation of the Immunization Practices Advisory Committee Meningococcal Vaccines ... PROSPECTS FOR FUTURE MENINGOCOCCAL VACCINES. Work is continuing on a serogroup B meningococcal vaccine, as well as on improved ... MENINGOCOCCAL DISEASE. MENINGOCOCCAL POLYSACCHARIDE VACCINES. RECOMMENDATIONS FOR VACCINE USE. PRECAUTIONS AND ... MENINGOCOCCAL POLYSACCHARIDE VACCINES. The recently licensed quadrivalent A,C,Y,W-135 vaccine (MenomuneR--A/C/Y/W-135, ...
... and W-135 types of meningococcal bacteria, who should and should not get the vaccine, benefits, and possible reactions after ... Meningococcal Quadrivalent polysaccharide and conjugate vaccine information, protection against A, C, Y, ...
Serogroup B Meningococcal Vaccine (MenB): learn about side effects, dosage, special precautions, and more on MedlinePlus ... Serogroup B meningococcal (MenB) vaccines can help prevent meningococcal disease caused by serogroup B. Other meningococcal ... For best protection, more than 1 dose of a serogroup B meningococcal vaccine is needed. The same vaccine must be used for all ... Two serogroup B meningococcal group B vaccines (Bexsero and Trumenba) have been licensed by the Food and Drug Administration ( ...
... researchers have examined the efficacy of a new vaccine against serogroups of Neisseria meningitides, which unlike the four out ... In this context, adding a meningococcal B vaccine as a standalone or eventually combined vaccine can be foreseen for both ... "Group B Meningococcal Disease - New Vaccine Shows Promise." Medical News Today. MediLexicon, Intl., 19 Jan. 2012. Web.. 19 Feb ... Rattue, P. (2012, January 19). "Group B Meningococcal Disease - New Vaccine Shows Promise." Medical News Today. Retrieved from ...
MENINGOCOCCAL POLYSACCHARIDE VACCINE (muh ning goh KOK kal vak SEEN) is a vaccine to protect from bacterial meningitis. ... Meningococcal Polysaccharide Vaccine injection. What is this medicine?. MENINGOCOCCAL POLYSACCHARIDE VACCINE (muh ning goh KOK ... This vaccine, like all vaccines, may not fully protect everyone.. Report any side effects that are worrisome to your doctor ... an unusual or allergic reaction to meningococcal vaccine, latex, other medicines, foods, dyes, or preservatives ...
... , Menactra, Menveo, MCV4, Quadrivalent Meningococcal Conjugate Vaccine. ... Tetravalent Meningococcal Conjugate Vaccine. *Covers strains A, C, W-135, Y (same as Menomune). *Serotypes C and Y each account ... Vaccine has no preservative (single use vial). *Does not contain thimerosal (contrast with prior MenomuneVaccine) ... Reasons for not including serotype B in Vaccine. *B has poor immunogenicity in Vaccine ...
Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: ... Adoption of Serogroup B Meningococcal Vaccine Recommendations. Allison Kempe, Mandy A. Allison, Jessica R. MacNeil, Sean T. ... the use of a quadrivalent meningococcal conjugate vaccine against serogroups A, C, W, and Y meningococcal (MenACWY). The ... and the duration of protection of the MenB vaccine. The existence of a recommendation for another meningococcal vaccine ( ...
ACIP recommends meningococcal vaccine for adolescents and college freshman. Meningococcal conjugate vaccine. Meningococcal ( ... should receive 23-valent pneumococcal vaccine and meningococcal vaccine, with Haemophilus influenzae type B vaccine ... children aged 2 to 10 years that compared meningococcal conjugate vaccine with meningococcal polysaccharide vaccine, serum ... 2007 meeting to state that meningococcal conjugate vaccine is preferable to meningococcal polysaccharide vaccine for ...
Meningococcal Group A, C, W135 and Y conjugate vaccine) for infants aged at least two months for approval. ... In my practice I have seen the devastating effects of meningococcal disease in infants. Meningococcal vaccines are being ... Meningococcal meningitis is caused by infection with the meningococcal bacterium Neisseria meningitides. Meningococcal disease ... Menveo Vaccine Trial Shows Promise For Infant Meningococcal Disease Protection. Published Monday 25 October 2010 Published Mon ...
GSKs Bexsero the only vaccine for now and is struggling to meet demand ... GSK takes case against Pfizer over meningococcal vaccine. GSKs Bexsero the only vaccine for now and is struggling to meet ... GlaxoSmithKlines meningococcal group B vaccine Bexsero is currently the only available in most markets and is in such high ... The vaccine is designed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals ...
... meningococcal polysaccharide vaccine) discontinuation. Sanofi Pasteur, the manufacturer of meningococcal polysaccharide vaccine ... should receive a quadrivalent meningococcal conjugate vaccine (Menactra or Menveo) instead.. More Information. *Meningococcal ... People in this age group who need a meningococcal vaccine, such as travelers to the "meningitis belt" (map) in Africa or ... With the discontinuation of Menomune, no meningococcal polysaccharide vaccines licensed for use in people 56 years of age are ...
Read the side effects of Meningococcal Conjugate Vaccine as described in the medical literature. In case of any doubt consult ... Meningococcal Conjugate Vaccine - Information. Meningococcal Conjugate Vaccine is a vaccine, prescribed for bacterial ... Side effect(s) of Meningococcal Conjugate Vaccine Read the side effects of Meningococcal Conjugate Vaccine as described in the ...
nonconjugate) meningococcal vaccine, or monovalent/bivalent meningococcal vaccine.-. Subjects receiving any allergen ... Previous vaccination with any meningococcal group B vaccine, any purely polysaccharide (nonconjugate) meningococcal vaccine, or ... Meningococcal VaccineA Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In ... Meningococcal VaccineA Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules NCT04440176 ...
... voted that all 11-12 year olds be administered a meningococcal vaccine though data was not sufficient enough to determine its ... be vaccinated with a meningococcal conjugate vaccine as well as a Men B vaccine, all meningococcal vaccine package inserts ... As with meningococcal conjugate vaccines, meningococcal serogroup B (MenB) vaccines received FDA approval based on blood tests ... Further, data was not available to determine whether the vaccine could reduce or eliminate vaccine type meningococcal bacteria ...
  • Shortly after, case reports of Guillain-Barré after Menactra vaccination were reported to the Vaccine Adverse Event Reporting System (VAERS). (cdc.gov)
  • No. Two large studies external icon were conducted to investigate whether GBS was caused by the vaccine or was coincidental with vaccination. (cdc.gov)
  • More information is available on CDC's Meningococcal Vaccination webpage. (cdc.gov)
  • Yih WK, Weintraub E, Kulldorff M. No risk of Guillain-Barré syndrome found after meningococcal conjugate vaccination in two large cohort studies external icon . (cdc.gov)
  • Vaccination is the best way to prevent meningococcal disease. (healthline.com)
  • As many as half the people who get meningococcal ACWY vaccine have mild problems following vaccination, such as redness or soreness where the shot was given. (medlineplus.gov)
  • The meningococcal B vaccine (MenB) protects against a fifth type of meningococcal bacterium (called type B). It is fairly new and not yet recommended as a routine vaccination for healthy people. (kidshealth.org)
  • Whenever feasible, the same brand of vaccine should be used for all doses of the vaccination series, because evidence is limited regarding the interchangeability of meningococcal vaccine products from different manufacturers. (medscape.com)
  • CDC: "Meningococcal Vaccines: What You Need to Know," "Meningococcal Vaccination. (webmd.com)
  • The maintenance of cold chain for the delivery of vaccines leads to rise in cost of vaccination, is the restraining factor for the market growth. (bccresearch.com)
  • however, since routine vaccination of recruits with the bivalent A/C vaccine began in 1971, disease caused by those serogroups has been uncommon. (cdc.gov)
  • More than half of the people who get serogroup B meningococcal vaccine have mild problems following vaccination. (medlineplus.gov)
  • Such reactions from a vaccine are very rare, estimated at about 1 in a million doses, and would happen within a few minutes to a few hours after the vaccination. (medlineplus.gov)
  • At present, the ACWY vaccine is used to protect people against four of the serotypes in the United States, whilst in Europe routine childhood vaccination with serogroup C meningococcal conjugate vaccines, which only protect against this particular serotype, have been successfully implemented. (medicalnewstoday.com)
  • A copy of the Vaccine Information Statements will be given before each vaccination. (nationwidechildrens.org)
  • The ACIP recommends serogroup B meningococcal vaccination for people aged 10 years and older at elevated risk for meningococcal disease. (aetna.com)
  • The ACIP also states that serogroup B meningococcal vaccination series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of group B meningococcus. (aetna.com)
  • Previous vaccination with any meningococcal group B vaccine, any purely polysaccharide (nonconjugate) meningococcal vaccine, or monovalent/bivalent meningococcal vaccine. (pfizer.com)
  • However, the CDC's Advisory Committee on Immunization Practices (ACIP) also approved the vaccine for use when meningococcal vaccination was indicated. (nvic.org)
  • When the CDC's Advisory Committee on Immunization Practices (ACIP) initially recommended routine vaccination of all 11-12 year olds with Menactra meningococcal conjugate vaccine in 2005, committee members estimated that a single dose of the vaccine would be effective for an average of 22 years. (nvic.org)
  • Within one year after vaccination, the vaccine was determined to be between 49 and 91 percent effective, and between one and three years, this number decreased to between 44 and 83 percent. (nvic.org)
  • MenACWY-D vaccine was found to be only 25 to 79 percent effective by 3 to 8 years following vaccination. (nvic.org)
  • While the CDC's Advisory Committee on Immunization Practices (ACIP) recommends that all persons with complement component deficiencies as well as those taking the medication eculizumab (Soliris®) be vaccinated with a meningococcal conjugate vaccine as well as a Men B vaccine, all meningococcal vaccine package inserts state that these individuals will continue to remain at high risk of meningococcal disease even if they develop antibodies following vaccination. (nvic.org)
  • Exclusion criteria were pregnancy, compromised immune system, fever, receiving any vaccine or immunoglobulin in the preceding three months, typhoid vaccination within the previous three years, previous meningococcal vaccination, and a history of typhoid or meningococcal disease. (bmj.com)
  • Since the introduction of monovalent meningococcal serogroup C (MenC) glycoconjugate (MCC) vaccines and the implementation of national vaccination programmes, the incidence of MenC disease has declined markedly as a result of effective short-term vaccination and reduction in acquisition of MenC carriage leading to herd protection. (nih.gov)
  • NeisVac-C(®) has the greatest longevity of the currently licensed MCC vaccines in terms of antibody persistence, however antibody levels have been found to fall rapidly after early infant vaccination with two doses of all MCC vaccines - necessitating a booster at ∼12 months. (nih.gov)
  • This was evident by the increased uptake following new vaccination recommendations issued by the Centers for Disease Control and Prevention (CDC) in June 2007 calling for meningococcal immunization for all adolescents 11 years through 18 years of age. (news-medical.net)
  • Saudi Arabia requires vaccination with the quadrivalent vaccine for international travelers to Mecca for Hajj. (wikipedia.org)
  • The vaccine was introduced in mass vaccination campaigns starting in 2010 and to-date more than 200 million individuals between 1 and 29 years of age have been vaccinated. (uio.no)
  • Reports of breakthrough meningococcal disease after vaccination with MenACWYD were collected. (nih.gov)
  • This report provides an early estimate of MenACWYD effectiveness within 3 to 4 years after vaccination, and suggests that MenACWYD effectiveness is 80% to 85%, similar to the VE reported for meningococcal polysaccharide vaccine. (nih.gov)
  • Safety profiles were similar across vaccine groups, although PsA-TT recipients were more likely than PsACWY recipients to have tenderness and induration at the vaccination site. (nih.gov)
  • However, pregnancy or breastfeeding are not reasons to avoid meningococcal ACWY vaccination. (cigna.com)
  • Talk with your teen's clinician if you are interested in serogroup B meningococcal vaccination. (infectioncontroltoday.com)
  • The purpose of the study is to see which of the three current provincial Meningococcal C Conjugate vaccine schedules in Canada provide the longest lasting protection against Meningococcal C disease and to see if a booster vaccination is needed. (clinicaltrials.gov)
  • A booster vaccination of the current provincial Men C vaccine will be provided at 12 months. (clinicaltrials.gov)
  • To evaluate the longest lasting protection against Meningococcal C disease and to see if a booster vaccination is needed. (clinicaltrials.gov)
  • What other kinds of reaction symptoms should I call to report after meningococcal vaccination? (nvic.org)
  • NVIC recommends consumers read the more complete information following the 'Quick Facts', as well as the vaccine manufacturer product information inserts, and speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. (nvic.org)
  • Previous vaccination with any meningococcal serogroup B vaccine. (pfizer.com)
  • Vaccination with any diphtheria, tetanus, pertussis, or poliomyelitis virus vaccine within 5 years of the first study vaccination. (pfizer.com)
  • Received any investigational drugs, vaccines or devices within 28 days before administration of the first study vaccination. (pfizer.com)
  • These antigens are found on the bacteria, and vaccination with them helps protect an individual from infection by the bacteria that carry the antigens, contingent on their immune response to the vaccine. (asm.org)
  • In 2015, two meningococcal B (MenB) vaccines were given a Category B recommendation by the Advisory Committee on Immunization Practices with a preferred vaccination window of 16-18 years," researchers led by Kristen A. Feemster, MD , MPH, wrote in an abstract presented at the Pediatric Academic Societies meeting. (mdedge.com)
  • Receipt of any vaccine in the 4 weeks preceding the first study vaccination or planned receipt of any vaccine in the 4 weeks before and/or following any study vaccination except for influenza vaccination and rotavirus vaccination, which may be received at a gap of at least 2 weeks before or 2 weeks after any study vaccines. (centerwatch.com)
  • This exclusion criterion does not apply to subjects in Finland who plan to receive the licensed rotavirus vaccine during study vaccination visits. (centerwatch.com)
  • Are there recommendations for meningococcal ACWY vaccination for people who reside in homeless shelters or halfway houses? (immunize.org)
  • Meningococcal disease is one of the most feared and serious infections in the young and its prevention by vaccination is an important goal. (ox.ac.uk)
  • The effectiveness of serogroup C glycoconjugate vaccines in children of all ages has been demonstrated and they have now been introduced into routine vaccination schedules. (ox.ac.uk)
  • Vaccination should be avoided by persons with known hypersensitivity (severe allergic reaction) to any ingredient of the vaccine, including latex (which is used in the vial stopper), or by any persons previously diagnosed with Guillain-Barre syndrome. (bio-medicine.org)
  • Vaccination with Menactra vaccine may not protect all individuals. (bio-medicine.org)
  • The company is currently involved in a 200 million $ contract with the New Zealand health authorities to supply a meningococcal vaccine for a mass vaccination program expected to cover more than a million children in that country. (newmediaexplorer.org)
  • Abstract BACKGROUND: The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of 1-29-year-olds in Burkina Faso in 2010. (omicsonline.org)
  • METHODS: We conducted a repeated cross-sectional meningococcal carriage study in a representative portion of the 1-29-year-old population in 3 districts in Burkina Faso before and up to 13 months after vaccination. (omicsonline.org)
  • Meningococcal disease is caused by a bacteria that can lead to bacterial meningitis and meningococcemia, which meningococcal vaccines can prevent. (sheknows.com)
  • A vaccine to prevent meningococcal meningitis , an inflammation of the membranes that cover the brain and spinal cord due to bacterial infection by an organism called Neisseria meningitidis. (medicinenet.com)
  • Meningococcal meningitis is a bacterial form of meningitis, a serious infection of the thin lining that surrounds the brain and spinal cord. (google.com)
  • If untreated, meningococcal meningitis is fatal in 50% of cases and may result in brain damage, hearing loss or disability in 10% to 20% of survivors. (google.com)
  • Before the vaccine, meningococcal disease was the leading cause of bacterial meningitis (an infection in the fluid around the brain and spinal cord) in children in the United States. (babycenter.com)
  • The meningococcal vaccines protect against meningococcal disease, which can lead to bacterial meningitis and other serious infections. (kidshealth.org)
  • Pregnant women can get the meningococcal vaccine, but it's only recommended for those with certain immune problems or those likely to be exposed to meningitis. (webmd.com)
  • National Meningitis Association: "About Meningococcal Disease. (webmd.com)
  • The rising incidence of meningitis across the world has been majorly fueling the growth of the global meningococcal vaccines market. (bccresearch.com)
  • Furthermore, World Health Organization is promoting strategies for prevention of meningitis and is hoping to introduce this vaccine in a moderate or high rate of disease countries of African region, which are suffering from meningitis and they hope to achieve. (bccresearch.com)
  • The case-fatality rate is approximately 10% for meningococcal meningitis and 20% for meningococcemia, despite therapy with antimicrobial agents, such as penicillin, to which all strains remain highly sensitive. (cdc.gov)
  • In a study published Online First in The Lancet , researchers have examined the efficacy of a new vaccine against serogroups of Neisseria meningitides, which unlike the four out of six existing safe and efficacious vaccines, also includes protection against serotype B. Serogroups of Neisseria meningitides cause meningococcal diseases, including meningitis . (medicalnewstoday.com)
  • MENINGOCOCCAL POLYSACCHARIDE VACCINE (muh ning goh KOK kal vak SEEN) is a vaccine to protect from bacterial meningitis. (nationwidechildrens.org)
  • Meningococcal meningitis, caused by the bacterium Neisseria meningitidis , is a potentially fatal bacterial infection that afflicts between 2500 and 3000 persons in the United States each year. (aetna.com)
  • Meningococcal meningitis is caused by infection with the meningococcal bacterium Neisseria meningitides . (medicalnewstoday.com)
  • Meningococcal disease is the leading cause of bacterial meningitis and sepsis (bloodstream infection). (medicalnewstoday.com)
  • Last month Glaxo said sales of its meningitis vaccine had doubled in the third quarter, forcing the company to race to bring new manufacturing capacity online. (irishtimes.com)
  • Meningococcal disease is a life-threatening illness caused by bacteria that infect the bloodstream (sepsis) and the lining that surrounds the brain and spinal cord (meningitis). (irishtimes.com)
  • People in this age group who need a meningococcal vaccine, such as travelers to the "meningitis belt" ( map ) in Africa or pilgrims to the Hajj in Saudi Arabia, should receive a quadrivalent meningococcal conjugate vaccine (Menactra or Menveo) instead. (cdc.gov)
  • Meningococcal bacteria can infect the spinal cord and brain, causing meningitis that can be fatal. (drugs.com)
  • One category protects against Serogroups A, C, W and Y meningococcal disease and another category that protects against Serogroup B meningitis. (youngwomenshealth.org)
  • Meningococcal meningitis is a potentially life-threatening bacterial infection. (citadel.edu)
  • Fortunately we have never had a case of meningococcal meningitis at The Citadel. (citadel.edu)
  • Meningococcal vaccine will protect against four of five common forms of Nisseria Meningitis, however no vaccine is guaranteed to protect 100% of individuals. (citadel.edu)
  • The meningococcal vaccine protects against meningococcal disease, a serious bacterial infection that can lead to bacterial meningitis . (rchsd.org)
  • Developing meningitis (infection of the spinal cord and lining of the brain) is much more dangerous to your health than receiving this vaccine. (cardiosmart.org)
  • Meningococcal disease is a rare but serious bacterial infection that strikes between 1,400 and 2,800 Americans every year, causing meningitis or sepsis in the majority of cases. (news-medical.net)
  • In the African meningitis belt efforts to immunize all people between the ages of one and thirty with the meningococcal A conjugate vaccine are ongoing. (wikipedia.org)
  • This project aims to assess the ability of meningococcal vaccines to prevent meningitis epidemics in the region. (uio.no)
  • Through a public-private partnership between the World Health Organization (WHO) and the Program for Appropriate Technology in Health (PATH), an affordable polysaccharide conjugate vaccine (MenAfriVac) has been developed for preventive mass immunization against MenA in the meningitis belt. (uio.no)
  • Thus, an affordable vaccine that can provide broad protection against all main serogroups causing meningococcal meningitis in Africa is highly needed. (uio.no)
  • These groups cause nearly all of the meningococcal meningitis cases in the U.S. The vaccine will not protect against infection caused by other meningococcal bacteria groups, such as Group B. (mayoclinic.org)
  • Meningococcal infection can cause life-threatening illnesses, such as meningococcal meningitis, which affects the brain, and meningococcemia, which affects the blood. (mayoclinic.org)
  • Some persons with meningococcal meningitis and/or meningococcemia may die. (mayoclinic.org)
  • New research from experts at the University of Nottingham could lead to an improved vaccine to protect against the bacterium, Neisseria meningitides that causes sepsis and meningitis. (news-medical.net)
  • Meningococcal infections are the most common cause of bacterial meningitis in the UK and Ireland, a life-threatening disease that poses a continuing threat worldwide. (news-medical.net)
  • Sanofi announced on Nov. 23, 2020 that the European Commission (EC) approved MenQuadfi (meningococcal [groups A, C, Y, W] conjugate vaccine) for immunization against meningococcal meningitis, the inflammation of the brain and spinal cord caused by a viral infection, in patients from the age of 12 months and older. (pharmtech.com)
  • Meningococcal meningitis can take one's life in as little as one day and leave survivors with severe permanent disabilities. (pharmtech.com)
  • Meningococcal disease can cause meningitis (infection of the lining of the brain and spinal cord) and infections of the blood. (cigna.com)
  • Symptoms of meningococcal meningitis may include sudden onset of a high fever, headache, or stiff neck. (infectioncontroltoday.com)
  • NVIC "Quick Facts" is not a substitute for becoming fully informed about Meningococcal disease, meningitis and the Meningococcal vaccine. (nvic.org)
  • Your child should get the meningococcal (MCV4) vaccine for protection against bacteria that can cause meningitis, an inflammation of the membranes that cover the brain and spinal cord. (sharecare.com)
  • First approved in the UK in 2000, NeisVac-C is one of the first meningococcal conjugate vaccines to be used in active immunization against meningococcal meningitis, specifically MenC. (sbwire.com)
  • Meningococcal disease usually presents clinically as meningitis (about 50% of cases), bacteremia (38% of cases), or bacteremic pneumonia (9% of cases). (immunize.org)
  • Meningococcal and Hib diseases are caused by potentially deadly bacteria that can lead to meningitis and other very serious complications. (gsk.com)
  • Because Hib vaccine can prevent meningitis, pneumonia, epiglottis inflammation and other serious infection caused by Hib bacteria, the WHO suggested that Hib vaccine should be included in the infant's normal immune programming. (clinicaltrials.gov)
  • Since the use of meningitis aureus polysaccharide vaccine, incidence of a disease in recent years is declined and maintain to the level of 0.5 per 1/100 thousand. (clinicaltrials.gov)
  • But meningitis aureus polysaccharide vaccine with a relatively poor immune response in the infants under the age of two, and the remaining 60% with a low antibody level and a short duration. (clinicaltrials.gov)
  • Invasive meningococcal disease (IMD) usually presents as an acute febrile illness with rapid onset and features of meningitis or septicemia (meningococcemia), or both, and a characteristic non-blanching rash. (canada.ca)
  • Meningococcal disease, which includes meningitis, is a serious bacterial infection that strikes between 1,000 and 2,600 Americans each year. (bio-medicine.org)
  • Prevents meningitis (meningococcal infection). (limamemorial.org)
  • Quadrivalent meningococcal conjugate vaccines. (nih.gov)
  • Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. (nih.gov)
  • Available quadrivalent meningococcal conjugate vaccines, which protect against serogroups A, C, W-135, and Y, are Menactra (Sanofi Pasteur) and Menveo (Novartis). (medscape.com)
  • As with meningococcal conjugate vaccines, meningococcal serogroup B (MenB) vaccines received FDA approval based on blood tests indicating immune response (immunogenicity) to the particular strains found within the vaccine. (nvic.org)
  • Monovalent and quadrivalent conjugate vaccines are commonly used vaccines to provide protection against MenC disease worldwide. (nih.gov)
  • There are three vaccines available in the United States to prevent meningococcal disease, all quadrivalent in nature, targeting serogroups A, C, W-135, and Y: three conjugate vaccines (MCV-4), Menactra, Menveo and MenQuadfi. (wikipedia.org)
  • Since the last policy statement from the American Academy of Pediatrics (AAP) concerning meningococcal vaccine was published in 2011, 2 meningococcal conjugate vaccines have been licensed for use in infants (Hib-MenCY-TT and MenACWY-CRM). (aappublications.org)
  • Conjugate vaccines against other serogroups, including A, Y, and W135 will soon be available and it is hoped they may emulate this success. (ox.ac.uk)
  • Serogroup C meningococcal polysaccharide conjugate vaccines were introduced in the United Kingdom in 1999, but the sequence types of meningococci causing disease since that time have not yet been reported. (asm.org)
  • Polysaccharide conjugate vaccines are providing essential and highly effective immunization against some of the major human pathogens ( 1 , 13 , 19 , 20 , 24 ). (asm.org)
  • The purpose of this trial is to assess if the rate of febrile reactions following the co-administration of a booster dose of pneumococcal conjugate vaccines with standard infant vaccines i. (bioportfolio.com)
  • Pneumococcal conjugate vaccines have potential to prevent significant proportion of childhood pneumonia. (bioportfolio.com)
  • Who gets meningococcal disease? (sheknows.com)
  • The meningococcal vaccine helps prevent the meningococcal disease caused by a bacterium called meningococcus. (sheknows.com)
  • Meningococcal disease is a highly contagious bacterial illness. (healthline.com)
  • This means they protect against four types of meningococcal disease. (healthline.com)
  • Meningococcal disease is potentially fatal and should always be viewed as a medical emergency. (google.com)
  • This vaccine and others in development offer the potential to broaden population protection against meningococcal disease. (nih.gov)
  • What is meningococcal disease? (medlineplus.gov)
  • Meningococcal disease is a serious illness caused by a type of bacteria called Neisseria meningitidis . (medlineplus.gov)
  • Meningococcal disease often occurs without warning, even among people who are otherwise healthy. (medlineplus.gov)
  • Meningococcal disease can spread from person to person through close contact (e.g., coughing, kissing) or lengthy contact, especially among people living in the same household. (medlineplus.gov)
  • Even when it is treated, meningococcal disease kills 10 to 15 infected people out of 100. (medlineplus.gov)
  • Meningococcal ACWY vaccines can help prevent meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available to help protect against serogroup B. (medlineplus.gov)
  • A pregnant or breastfeeding woman should be vaccinated if she is at increased risk of meningococcal disease. (medlineplus.gov)
  • This vaccine protects against the bacteria Neisseria meningitidis , which causes meningococcal disease. (babycenter.com)
  • In 2017, there were about 350 reports of meningococcal disease in the United States. (babycenter.com)
  • Ten to 15 out of 100 people infected with meningococcal disease die. (babycenter.com)
  • Meningococcal disease can also cause serious problems like loss of limbs, deafness, intellectual disability, and stroke. (babycenter.com)
  • Children younger than 1 and people ages 16 to 23 are the most likely to contract meningococcal disease. (babycenter.com)
  • According to the U.S. Centers for Disease Control and Prevention (CDC), the vaccine protects about 98 percent of those who are immunized. (babycenter.com)
  • The vaccine protects against most types of meningococcal disease, but it doesn't prevent all cases. (babycenter.com)
  • Invasive meningococcal disease is a rare but serious infection caused by Neisseria meningitides, or meningococcus, bacteria. (mercola.com)
  • Some types of MenACWY are given to younger children (as early as 8 weeks of age) if they have a higher risk of getting meningococcal disease. (kidshealth.org)
  • But some kids and teens who are at increased risk for meningococcal disease should get it starting from age 10. (kidshealth.org)
  • Kids and teens who are at higher risk for meningococcal disease need the full series of MenACWY vaccines, even if they're younger than 11 years old. (kidshealth.org)
  • The meningococcal vaccines contains only a small piece of the germ, so it can't cause meningococcal disease. (kidshealth.org)
  • In 2005, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the [AAP] developed recommendations for the use of [MCV4] with the objective of protecting adolescents as well as young adults aged 16 through 21 years, the time at which meningococcal disease rates peak," write Michael T. Brady, MD, and colleagues from the AAP's Committee on Infectious Diseases, 2010-2011. (medscape.com)
  • Persons at increased risk for invasive meningococcal disease should receive a 2-dose primary series 2 months apart. (medscape.com)
  • A booster dose should be given every 5 years for persons whose 2-dose primary series or booster dose was given at 7 years of age or older who are at risk for invasive meningococcal disease because of persistent complement component deficiency or functional or anatomic asplenia. (medscape.com)
  • Some states, secondary schools, colleges, or universities have policies that require immunization against meningococcal disease as a condition of enrollment," the policy statement authors conclude. (medscape.com)
  • National Network for Immunization Information: "Vaccine Information: Meningococcal Disease," "Frequently Asked Questions about the Meningococcal Vaccine. (webmd.com)
  • A polysaccharide vaccine against disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 is currently licensed in the United States. (cdc.gov)
  • No major epidemic of meningococcal disease has occurred in the United States since 1946, although localized community outbreaks have been reported. (cdc.gov)
  • The incidence of endemic meningococcal disease peaks in the late winter to early spring. (cdc.gov)
  • Meningococcal disease is particularly common among individuals with component deficiencies in the final common complement pathway (C3, C5-C9), many of whom experience multiple episodes of infection (2). (cdc.gov)
  • Asplenic persons seem also to be at increased risk of developing meningococcal disease and experience particularly severe infections (3). (cdc.gov)
  • It is uncertain whether individuals with other diseases associated with immunosuppression are at higher risk of acquiring meningococcal disease, as they are for disease caused by other encapsulated bacteria. (cdc.gov)
  • Serogroup B meningococcal (MenB) vaccines can help prevent meningococcal disease caused by serogroup B. Other meningococcal vaccines are recommended to help protect against serogroups A, C, W, and Y. (medlineplus.gov)
  • Even though serotype B is the most prevalent strain across South America, it is also common in high-income countries causing much of the remaining meningococcal disease burden. (medicalnewstoday.com)
  • This has resulted in serogroup B becoming a major cause of meningococcal disease in Europe and other continents, presenting a significant medical and societal burden. (medicalnewstoday.com)
  • Although many providers reported not knowing about factors influencing recommendation decisions, MenB disease outbreaks (89%), disease incidence (62%), and effectiveness (52%), safety (48%), and duration of protection of MenB vaccine (39%) increased the likelihood of recommendation, whereas the Category B recommendation (45%) decreased likelihood. (aappublications.org)
  • Primary care physicians have significant gaps in knowledge about MenB disease and the MenB vaccine, and this appears to be a major driver of the decision not to discuss the vaccines. (aappublications.org)
  • Significant gaps in knowledge about MenB disease and the MenB vaccine exist and appear to be a major driver of decisions not to discuss the vaccine. (aappublications.org)
  • Meningococcal disease has an overall case-fatality ratio of ∼10% to 15%, and permanent severe sequelae are common among survivors, 1 - 3 heightening the importance of preventing this deadly infection. (aappublications.org)
  • At the same time, meningococcal disease caused by any serogroup is uncommon in the United States and has been decreasing 4 since the mid-1990s because of a variety of reasons, including natural decline and, among adolescents and young adults, the use of a quadrivalent meningococcal conjugate vaccine against serogroups A, C, W, and Y meningococcal (MenACWY). (aappublications.org)
  • Meningococcal disease caused by serogroup B is also uncommon, with 130 cases in 2016, 41 of which were diagnosed in those aged 16 to 23 years. (aappublications.org)
  • Aetna considers meningococcal vaccine a medically necessary preventive service according to the recommendations of the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP). (aetna.com)
  • Aetna considers meningococcal group B vaccine (Trumenba, Bexsero) medically necessary to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 years of age and older according to the recommendations of the Centers for Disease Control and Preventions (CDC) Advisory Committee on Immunization Practices (ACIP). (aetna.com)
  • People at increased risk owing to an outbreak of serogroup B meningococcal disease. (aetna.com)
  • Approximately 10 percent of individuals who contract meningococcal disease will die. (aetna.com)
  • Advisory Committee on Immunization Practices (ACIP) currently recommends tetravalent or quadrivalent meningococcal conjugate vaccine for all 11 to 18 year olds and for persons aged 2 to 55 years who are at increased risk for meningococcal disease (CDC, 2007, 2010). (aetna.com)
  • The previous recommendations for meningococcal conjugate vaccine administration consisted of three cohorts: 11 to 12 year olds, adolescents entering high school (or 15 year olds), and other persons at increased risk for meningococcal disease, such as incoming college freshmen who would be living in dormitories. (aetna.com)
  • The company announced the vaccine offers protection against four major serogroups of meningococcal disease at the Infectious Disease Society of America (IDSA) 48th meeting, Vancouver, Canada. (medicalnewstoday.com)
  • In my practice I have seen the devastating effects of meningococcal disease in infants. (medicalnewstoday.com)
  • Meningococcal vaccines are being developed that can provide broad protection against the disease in this vulnerable population. (medicalnewstoday.com)
  • These data are another step in the significant progress Novartis is making toward our goal of protecting all age groups against meningococcal disease. (medicalnewstoday.com)
  • The vaccine is designed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals aged between ten and 25 years. (irishtimes.com)
  • By this time, data on vaccine effectiveness had determined that by age 16 to 21 years, at a time when the risk of meningococcal disease was determined to be higher, more than 50 percent of 11-12 year olds would lack any protection from the vaccine and be at risk for developing meningococcal disease. (nvic.org)
  • Moreover, with meningococcal serogroup B disease rates at historical lows and disease outbreaks sporadic even prior to the licensing of TRUMENBA (MenB-FHbp) and BEXSERO (MenB-4C) vaccines, data on the effectiveness of meningococcal group B vaccines was considered almost impossible to attain. (nvic.org)
  • Meningococcal disease can also lead to permanent and disabling medical problems. (drugs.com)
  • Meningococcal disease can spread from one person to another through small droplets of saliva that are expelled into the air when an infected person coughs or sneezes. (drugs.com)
  • Meningococcal disease is more likely to occur in babies younger than 1 year, in young people ages 16 to 23 years, in anyone with a weak immune system, and in anyone exposed to an outbreak of the disease. (drugs.com)
  • The vaccine works by exposing you to a small dose of the bacteria or a protein from the bacteria, which causes your body to develop immunity to the disease. (drugs.com)
  • Like any vaccine, meningococcal polysaccharide vaccine may not provide protection from disease in every person. (drugs.com)
  • you have been exposed to an outbreak of meningococcal disease. (drugs.com)
  • Be sure to receive all recommended doses of this vaccine or you may not be fully protected against disease. (drugs.com)
  • Meningococcal vaccines protect against most types of this disease. (youngwomenshealth.org)
  • How is meningococcal disease spread? (youngwomenshealth.org)
  • Who is at risk for getting meningococcal disease? (youngwomenshealth.org)
  • Anybody at any age can get meningococcal disease. (youngwomenshealth.org)
  • How is meningococcal disease treated? (youngwomenshealth.org)
  • Meningococcal disease is treated with antibiotics such as penicillin. (youngwomenshealth.org)
  • Scientists believe it is better than the MPSV4 and protection against meningococcal disease appears to be longer too. (youngwomenshealth.org)
  • MPSV4 (Menomune) was made available in the 1970's and is given to those over 2 years old who are at higher risk of meningococcal disease. (youngwomenshealth.org)
  • It protects against four serotypes of meningococcal disease: types A, C, W and Y. (youngwomenshealth.org)
  • The American College Health Association (ACHA) estimates that 100-125 cases of meningococcal disease occur annually on college campuses (mostly among freshmen living in dorms), and 5 to 15 students will die as a result. (citadel.edu)
  • The Centers for Disease Control recommends that the best time to get this vaccine is between the ages of 16 and 18 years old. (cigna.com)
  • Meningococcal disease is caused by the bacterium Neisseria meningitides . (rchsd.org)
  • If your child has a history of Guillain-Barré syndrome (a disease of the nervous system that causes progressive weakness), talk to your doctor about whether the vaccine is a good idea. (rchsd.org)
  • The CDC's Advisory Committee on Immunization Practices (ACIP) voted last year to issue a Category B (www.cdc.gov) recommendation for the use of two serogroup B meningococcal (MenB) vaccines in patients ages 16-23 for short-term protection against the disease, with a preference for administration between ages 16 and 18. (aafp.org)
  • Previously, the ACIP had recommended the vaccines -- Pfizer's Trumenba, which is given as a three-dose series, and Novartis' Bexsero, which is given as a two-dose series -- only for people ages 10 and older who are at increased risk for serogroup B meningococcal disease. (aafp.org)
  • The major argument in favor of getting one of the vaccines is that they protect patients from a disease that results in a high incidence of death and disability. (aafp.org)
  • All serotypes of meningococcal disease are rare, and the incidence seems to be decreasing. (aafp.org)
  • Since 2009, seven outbreaks of serogroup B meningococcal disease have occurred on college campuses. (aafp.org)
  • As to how effective the MenB vaccines are in preventing meningococcal B infections, the fellows said clinical trials of vaccine effectiveness are not practical or possible because the incidence of disease is so low. (aafp.org)
  • Menomune® - A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, is indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. (rxlist.com)
  • Menomune - A/C/Y/W-135 vaccine does not prevent N meningitidis serogroup B disease. (rxlist.com)
  • The lack of an anti-capsular vaccine against serogroup B meningococcal disease has necessitated the exploration of alternative vaccine candidates, mostly proteins exhibiting varying degrees of antigenic variation. (eurosurveillance.org)
  • Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. (eurosurveillance.org)
  • O'Hallahan J , Lennon D , Oster P . The strategy to control New Zealand's epidemic of group B meningococcal disease. (eurosurveillance.org)
  • Efficacy evaluation of the Cuban vaccine VA-MENGOC-BC against disease caused by serogroup B Neisseria meningitidis. (eurosurveillance.org)
  • Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. (eurosurveillance.org)
  • Menactra(R) vaccine is the first and only quadrivalent conjugate vaccine licensed in the U.S. for the prevention of meningococcal disease. (news-medical.net)
  • Meningococcal disease is serious and no healthy child should have to risk permanent disability, or even death, from this vaccine-preventable disease. (news-medical.net)
  • It is used to prevent meningococcal disease. (mskcc.org)
  • Guillain-Barré syndrome (GBS, nerve disease that causes paralysis), history of-May increase risk of developing GBS after receiving the vaccine. (mayoclinic.org)
  • Nimenrix (developed by GlaxoSmithKline and later acquired by Pfizer), is a quadrivalent conjugate vaccine against serogroups A, C, W-135, and Y. In April 2012 Nimenrix was approved as the first quadrivalent vaccine against invasive meningococcal disease to be administered as a single dose in those over the age of one year, by the European Medicines Agency. (wikipedia.org)
  • magazine has launched the Protect Our Kids campaign to ensure all children across Australia can be protected against deadly meningococcal disease. (change.org)
  • But what they didn't realise is that there are five deadly strains of meningococcal disease - A,B,C,W and Y - and currently, only the C vaccine is on the PBS. (change.org)
  • The Centers for Disease Control and Prevention (CDC) has published new recommendations, "Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices," which have been endorsed by the AAP. (aappublications.org)
  • Specific meningococcal serogroups appear to cause a preponderance of disease in certain age groups and geographic areas. (aappublications.org)
  • For unknown reasons, the incidence of meningococcal disease has decreased in the United States since the late 1990s. (aappublications.org)
  • Meningococcal vaccines are recommended routinely for adolescents and for selected groups of children at increased or persistent risk for invasive meningococcal disease ( Table 2 ). (aappublications.org)
  • The new indications and newly licensed vaccines address immunization of younger children at increased risk for meningococcal disease. (aappublications.org)
  • The development of a comprehensive vaccine against Neisseria meningitidis, the causative agent of meningococcal disease, has remained elusive because of bacterial diversity and immunologic evasion. (springer.com)
  • In Meningococcal Vaccines: Methods and Protocols, Andrew Pollard and Martin Maiden have assembled an impressive collection of the latest molecular and cellular techniques for the development, evaluation, and implementation of vaccines to be used against this dreaded disease. (springer.com)
  • Protein-conjugated polysaccharide vaccines against serogroup A, C, W and Y meningococcal disease have been developed for the Western market, but the price of these products is prohibitive to their use by developing countries. (uio.no)
  • PARENTS face a hefty bill if they want to protect their children from the deadly meningococcal B disease. (news.com.au)
  • PARENTS will face a $500 bill if they wish to protect their children from the deadly meningococcal B disease after a new vaccine was rejected for subsidy for a second time. (news.com.au)
  • Meningococcal disease is very rare, however once infected, the disease can progress quickly and with serious consequences. (toronto.ca)
  • The Advisory Committee on Immunization Practices recommends MenACWYD for all adolescents 11 to 18 years of age and others at increased risk for meningococcal disease. (nih.gov)
  • Meningococcal disease describes the clinical manifestations of invasive infection with the gram-negative bacteria Neisseria meningitides . (nap.edu)
  • 2008). In the United States in 2004, 1,400-2,800 cases of invasive meningococcal disease were reported (CDC, 2005). (nap.edu)
  • 2008). Pneumonia is also associated with meningococcal disease and occurs in 6 to 15 percent of patients (Racoosin et al. (nap.edu)
  • The risk of meningococcal disease is higher among asplenic individuals and those with deficiencies in the terminal common complement pathway of the immune system (CDC, 2005). (nap.edu)
  • Additionally, prior viral infection, crowding, active and passive smoking, attending bars or nightclubs, and imbibing in alcohol are all associated with higher risk of meningococcal disease (CDC, 2005). (nap.edu)
  • Prior to the development of antibiotics, approximately 70 to 85 percent of cases of meningococcal disease were fatal (Granoff et al. (nap.edu)
  • 2008). Ten to 20 percent of meningococcal disease survivors experience permanent sequelae such as limb loss, hearing loss, neurologic disability, and scarring (Granoff et al. (nap.edu)
  • Of these, five serogroups-A, B, C, W-135, and Y-are responsible for almost all instances of meningococcal disease (Granoff et al. (nap.edu)
  • 2008). In the United States, the majority of meningococcal disease is caused by serogroups B, C, and Y (Granoff et al. (nap.edu)
  • Although various vaccines against meningococcal disease have been available for more than 30 years, currently there is no vaccine to protect against all five of the pathogenic serogroups. (nap.edu)
  • Trumenba and Bexsero have both been approved for the prevention of serogroup B meningococcal disease in individuals aged 10 through 25 years by the American Academy of Pediatrics Committee on Infectious Diseases. (healio.com)
  • The committee issued a category A recommendation stating that either Trumenba (MenB-FHbp, Wyeth Pharmaceuticals) or Bexsero (MenB-4C, Novartis Vaccines) can be used routinely for individuals at increased risk for serogroup B meningococcal disease. (healio.com)
  • They are living in, working in, or visiting an area where there is a strong possibility of contracting meningococcal disease. (mayoclinic.org)
  • With growing fears around the increase of antibiotic-resistant bacteria, ensuring vaccines are as effective as they can be, could prove vital in helping reduce the number of global deaths from the disease. (news-medical.net)
  • This type of vaccine is however ineffective against MenB strains, the major agents of meningococcal disease in the UK. (news-medical.net)
  • In Europe, there were more than 3000 cases of Invasive Meningococcal Disease in 2018, half of them caused by serogroups C, W, and Y," said Thomas Triomphe, head of Sanofi Pasteur, in the press release. (pharmtech.com)
  • Meningococcal ACWY vaccine can help protect against meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can help protect against serogroup B. (cigna.com)
  • SILVER SPRING, Md. - The Food and Drug Administration last week announced approval for Bexsero, a vaccine intended to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 years through 25 years of age. (drugstorenews.com)
  • Bexsero is the second vaccine approved by the FDA in the past three months to prevent the disease. (drugstorenews.com)
  • Meningococcal disease is a life-threatening illness caused by bacteria that can infect the bloodstream, as well as the lining that surrounds the brain and spinal cord. (drugstorenews.com)
  • The Centers for Disease Control and Prevention says that close to 500 cases of meningococcal disease were reported in the United States in 2012. (drugstorenews.com)
  • With today's approval of Bexsero, the U.S. now has two vaccines for the prevention of serogroup B meningococcal disease," said Karen Midthun, M.D., director of the FDA's Center for Biologics Evaluation and Research. (drugstorenews.com)
  • The approval of these vaccines represents a major public health accomplishment toward preventing this life-threatening disease. (drugstorenews.com)
  • Meningococcal disease can be treated with antibiotics to reduce the risk of death and long-term complications, but even then these outcomes are not always prevented. (drugstorenews.com)
  • Meningococcal disease is not very common in the United States, but teens and young adults are at increased risk. (infectioncontroltoday.com)
  • There are licensed vaccines to help prevent the most common types of meningococcal disease in the United States. (infectioncontroltoday.com)
  • Meningococcal disease refers to any illness caused by Neisseria meningitidis bacteria. (infectioncontroltoday.com)
  • however, even with antibiotic treatment, 10 to 15 out of 100 people with meningococcal disease will die. (infectioncontroltoday.com)
  • People spread the bacteria that cause meningococcal disease to others by sharing respiratory and throat secretions (such as saliva or spit). (infectioncontroltoday.com)
  • People do not catch them through casual contact or by breathing air where someone with meningococcal disease has been. (infectioncontroltoday.com)
  • Only about 2 or 3 out of 100 meningococcal disease cases occur as part of an outbreak. (infectioncontroltoday.com)
  • Vaccines are developed using either dead strains of a disease, weakened strains, or strains of a different disease. (sharecare.com)
  • Boston, MA -- ( SBWIRE ) -- 08/21/2013 -- Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. (sbwire.com)
  • For these reasons the meningococcal disease space is dominated by vaccines. (sbwire.com)
  • Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. (sbwire.com)
  • This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how it is tolerated when given together with Repevax. (pfizer.com)
  • Washington, DC - November 22, 2017 - Up to 91 percent of bacterial strains causing a common type of invasive serogroup B meningococcal disease in children and young adults express at least one of the antigens contained in a four-component vaccine called MenB-4C (Bexsero), according to laboratory studies conducted by investigators at the federal Centers for Disease Control and Prevention (CDC) and at GlaxoSmithKline, manufacturers of the vaccine. (asm.org)
  • In the United States in 2015, serogroup B strains of the bacteria caused approximately 40 percent of invasive meningococcal disease in all age groups, including adolescents, and over 60 percent of cases in infants aged less than one year. (asm.org)
  • Another vaccine against serogroup B meningococcal disease, called Trumenba, was approved by the FDA in October 2014. (asm.org)
  • Previous vaccines were available to protect against meningococcal disease caused by N. meningitidis serogroups A, C, Y and W but not against serogroup B. (asm.org)
  • Increase in outbreaks of meningococcal disease and surge in immunization programs across the globe drive the growth of the global meningococcal vaccines market. (medgadget.com)
  • The vaccine is indicated for active immunisation against invasive meningococcal disease (IMD) caused by Neisseria meningitidis N meningitidis ) serogroups A, C, Y and W-135. (drugdevelopment-technology.com)
  • In April 2011, the vaccine was further approved by the FDA against meningococcal disease for infants of nine to 23 months. (drugdevelopment-technology.com)
  • Please tell us about meningococcal disease. (immunize.org)
  • Meningococcal disease is a bacterial infection caused by Neisseria meningitidis . (immunize.org)
  • Meningococcal disease can be severe. (immunize.org)
  • The incidence of meningococcal disease has declined since a peak of reported disease in the late 1990s. (immunize.org)
  • Even before routine use of a meningococcal conjugate vaccine (MenACWY) in adolescents was recommended in 2005, the overall annual incidence of meningococcal disease had decreased 64%, from 1.1 cases per 100,000 population in 1996 to 0.4 cases per 100,000 population in 2005. (immunize.org)
  • During 2005 2011, an estimated 800 1,200 cases of meningococcal disease occurred annually in the United States, representing an incidence of 0.3 cases per 100,000 population. (immunize.org)
  • What are the risk factors for meningococcal disease? (immunize.org)
  • Certain groups are at increased risk for meningococcal serogroups A, C, W, and Y but not serogroup B. These risk factors include HIV infection, travel to places where meningococcal disease is common (such as certain countries in Africa and in Saudi Arabia), and college students living in a dormitory. (immunize.org)
  • Since late 2014, vaccines have become available that offer protection from meningococcal serogroup B disease. (immunize.org)
  • MenACWY vaccines provide no protection against serogroup B disease, and meningococcal serogroup B vaccines (MenB) provide no protection against serogroup A, C, W, or Y disease. (immunize.org)
  • Novartis announced that the FDA has approved Menveo (meningococcal [Groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in children 2-10 years of age. (empr.com)
  • Menveo was initially approved in February 2010 for the active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people 11-55 years of age. (empr.com)
  • Risk and protective factors for meningococcal disease in adolescents: matched cohort study. (pfizerpro.com)
  • Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century-an update for the clinician. (pfizerpro.com)
  • Serogroup B meningococcal disease outbreak and carriage evaluation at a college-Rhode Island, 2015. (pfizerpro.com)
  • Clinical recognition of meningococcal disease in children and adolescents. (pfizerpro.com)
  • Brandtzaeg P. Chapter 21: Pathogenesis and pathophysiology of invasive meningococcal disease. (pfizerpro.com)
  • Monovalent (A or C) meningococcal vaccine, which protects against meningococcal group A and C disease. (who.int)
  • Monovalent C meningococcal vaccine is recommended for all children at one year of age as part of routine immunization and for people who have had meningococcal disease. (who.int)
  • This form is recommended for travelers to countries where there are epidemics of meningococcal disease (eg. (who.int)
  • There are no acceptable serologic titers that can be used as evidence of protection against meningococcal A, C, W, and Y disease. (immunize.org)
  • The hSBA, the only correlate of protection against invasive meningococcal disease accepted thus far, cannot conveniently be used to test large number of strains. (hindawi.com)
  • Meningococcal disease is a rare but deadly disease caused by the bacte. (bio-medicine.org)
  • Licensure of Menactra vaccine for infants as young as 9 months of age gives the opportunity to help protect infants against this potentially deadly disease when the likelihood of exposure supports a need for early protection, " said Stephen I. Pelton, MD, Professor of Pediatrics and Epidemiology, Boston University Schools of Medicine and Public Health and Chief, section of Pediatric Infectious Diseases, Boston Medical Center. (bio-medicine.org)
  • Menactra vaccine was the first quadrivalent conjugate vaccine licensed in the United States for active immunization against meningococcal disease caused by the serogroups contained in the vaccine (A, C, Y and W-135). (bio-medicine.org)
  • The approval of Menactra vaccine for infants is a significant advancement toward potentially eliminating the threat of this serious disease in this vulnerable population for included serogroups," said Michael Decker, MD, MPH, vice president, scientific and medical affairs at Sanofi Pasteur. (bio-medicine.org)
  • Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) is the only U.S. licensed conjugate vaccine for persons age 9 months through 55 years of age for active immunization against invasive meningococcal disease caused by N. meningitidis serogroups A, C, Y and W-135. (bio-medicine.org)
  • In 1981, Menomune® - A/C/Y/W-135 (Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined) became the first meningococcal vaccine available to help protect against meningococcal disease caused by four of the five most common serogroups (A, C, Y and W-135). (bio-medicine.org)
  • It would appear thus that meningococcal disease is both eminently preventable and even curable by simply supplying sufficient amounts vitamin C , a nutrient which is of great importance for health but which human bodies cannot manufacture, to those suffering from the infection or who might be at risk of contracting it. (newmediaexplorer.org)
  • During the 1990s, the incidence of meningococcal disease was high in the United Kingdom. (asm.org)
  • Serogroup C meningococcal disease became a particular problem in the United Kingdom during the 1990s and was associated with a high prevalence of the ET37/ST11 clone ( 6 , 16 ). (asm.org)
  • Prospective enhanced surveillance of those meningococci associated with throat carriage and invasive disease was initiated in the United Kingdom before the implementation of the meningococcal serogroup C conjugate (MenC) vaccines towards the end of 1999 ( 2 , 5 , 13 ). (asm.org)
  • An overall vaccine uptake of 85% was achieved in the United Kingdom for the whole population under 20 years of age ( 14 ), and the implementation of MenC vaccines has led to a reduced level of serogroup C meningococcal throat carriage and also a reduced level of invasive disease ( 13 , 14 , 17 , 18 ). (asm.org)
  • However, since the population dynamics of meningococcal disease are very fluid, with serogroup B and serogroup C historically undergoing a complementary cyclic pattern ( 7 , 16 ), it is essential to understand the intra- and interlineage population dynamics of this disease. (asm.org)
  • We used multilocus sequence typing (MLST) to characterize a collection of 432 meningococci, isolated from cases of invasive meningococcal disease before (1999) and during (2000, 2001, and 2002) the introduction of MenC vaccines (years 1 to 4) in Scotland. (asm.org)
  • Four hundred thirty-two isolates of N. meningitidis from patients with invasive meningococcal disease in Scotland were analyzed between 1999 and 2002 inclusive by MLST, a method which sequences internal fragments of seven housekeeping genes ( 6 , 12 ). (asm.org)
  • These isolates were isolated from normally sterile sites (blood and cerebrospinal fluid) from patients with meningococcal disease from all 15 National Health Service boards via their representative diagnostic hospital laboratories. (asm.org)
  • Invasive meningococcal disease caused by Neisseria meningitidis is a life-threatening disease. (bioportfolio.com)
  • Finnish Invasive Pneumococcal disease vaccine trial was designed to assess the vaccine effectiv. (bioportfolio.com)
  • A notable reduction of pneumococcal disease burden among adults was observed after introduction of 7 valent- pneumococcal conjugate vaccine in childhood immunization programs. (bioportfolio.com)
  • About 1,000 - 2,600 people get meningococcal disease each year in the U.S. Even when they are treated with antibiotics, 10-15% of these people die. (uintacounty.com)
  • Meningococcal vaccine is also recommended for other people at increased risk for meningococcal disease. (uintacounty.com)
  • This, however, contains only four strains, ACW and Y). Currently there is no licensed vaccine that is protective against Neisseria meningitidis group X which has caused multiple recent outbreaks in Africa and suggest a hyperendemicity and high capacity for localised epidemics. (google.com)
  • Menactra vaccine offers protection against four of the five most common serogroups of the bacterium that cause meningococcal infection, Neisseria meningitidis serogroups A, C, Y and W-135. (news-medical.net)
  • Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitidis. (wikipedia.org)
  • Immunogenicity and safety of the vaccine were assessed in 6300 individuals who received a single dose of MenQuadfi, which showed a good safety profile and induced a high immune response against all four Neisseria meningitidis serogroups. (pharmtech.com)
  • such as Neisseria lactamica are also possible vaccine candidates. (ox.ac.uk)
  • To investigate antigen-antibody interactions and assess the potential of the most common epitope mapping techniques, we generated a series of mAbs against factor H binding protein (fHbp), a key virulence factor and vaccine antigen of Neisseria meningitidis. (rcsb.org)
  • Meningococcal conjugate vaccine (MenACWY) is licensed by the Food and Drug Administration (FDA) for protection against serogroups A, C, W, and Y. (medlineplus.gov)
  • The researchers used whole genome sequencing to identify proteins on the surface of many meningococcal strains in their quest to develop a broad-spectrum vaccine against serogroup B. This method can potentially be applied to target all other serogroups. (medicalnewstoday.com)
  • An age-appropriate meningococcal vaccine that includes serogroups A and W is indicated for travelers to areas with high endemicity (parts of sub-Saharan Africa or the Hajj in Saudi Arabia). (aetna.com)
  • Aetna considers the use of saliva testing of antibody levels against meningococcal serogroups for monitoring meningococcal vaccine responses experimental and investigational because the effectiveness of this approach has not been established. (aetna.com)
  • A significant percentage of vaccinated infants "achieved robust immune response" against meningococcal serogroups A, C, W135 and Y. (medicalnewstoday.com)
  • ACWY-naïve participants: Participants who have never received a prior dose of a meningococcal vaccine containing ACWY serogroups. (pfizer.com)
  • Menactra (MCV4 or MenACWY-D), the first meningococcal (serogroups A,C, Y, and W-135) conjugate vaccine received FDA approval in January of 2005 on the basis that the vaccine was not inferior in safety or immunogenicity when compared with Menomune meningococcal polysaccharide vaccine, the only FDA approved meningococcal vaccine available at the time. (nvic.org)
  • Menveo (MenACWY-CRM), the second meningococcal (serogroups A, C, Y, and W-135) conjugate vaccine received FDA approval in February of 2010 based on safety and immunogenicity studies reporting the vaccine to be non-inferior to Menactra (MCV4/ MenACWY-D) vaccine. (nvic.org)
  • Both vaccines protect against Serogroups A, C, W, and Y. A booster shot is recommended at age 16-18. (youngwomenshealth.org)
  • When you receive a booster dose, make sure you are receiving a vaccine for meningococcal serogroup B and not for serogroups A, C, W, or Y. (cigna.com)
  • Despite high diversity, a limited number of antigenic variants of each of the vaccine antigens were prevalent, with strong associations of particular variant combinations with given serogroups and genotypes. (eurosurveillance.org)
  • Immune responses were significantly greater for all four serogroups in those who received Menactra(R) vaccine than those who received Menomune-A/C/Y/W-135 vaccine. (news-medical.net)
  • Declines in incidence have occurred in all serogroups, including serogroup B, which is currently not included in any meningococcal vaccine licensed in the United States. (aappublications.org)
  • In 2005, Sanofi Pasteur received approval for Menactra from the US FDA as the first meningococcal conjugate vaccine for immunisation against IMD caused by N meningitidis serogroups A, C, Y and W-135 in people aged between 11 and 55 years. (drugdevelopment-technology.com)
  • The vaccine induced the production of bactericidal antibodies specific to the capsular polysaccharides of the four serogroups found in the vaccine. (drugdevelopment-technology.com)
  • Since 2005, declines have occurred among all age groups and in all vaccine-contained serogroups. (immunize.org)
  • For all meningococcal serogroups risk factors include age, functional or anatomic asplenia, persistent complement component deficiency (an immune system disorder) including that caused by eculizumab (Soliris, Alexion Pharmaceuticals) used for treatment of atypical hemolytic uremic syndrome or paroxysmal nocturnal hemoglobinuria (the drug binds to C5 and inhibits the terminal complement pathway), and occupation as a microbiologist in a laboratory that works with meningococcal isolates. (immunize.org)
  • In the pivotal trial, the safety and immunogenicity of Menveo against each of the four serogroups were compared with those of the other currently US-licensed ACW-135Y meningococcal conjugate vaccine. (empr.com)
  • The proposed indication for this combination vaccine is immunization of infants and toddlers against meningococcal serogroups C & Y, and Haemophilus influenzae type b (Hib) diseases at two, four, six and 12-15 months of age. (gsk.com)
  • Results from these studies showed that 2 doses of Menactra vaccine given 3 months apart elicit a robust immune response against the serogroups included in the vaccine. (bio-medicine.org)
  • Meningococcal vaccines designed to help protect against serogroups A and C were introduced in the mid-1970s. (bio-medicine.org)
  • Does Menactra Meningococcal Conjugate Vaccine cause Guillain-Barré Syndrome (GBS)? (cdc.gov)
  • Another large 2012 study combined the above study with data from the Vaccine Safety Datalink to search for diagnoses of GBS in 11.2 million preteens and teens who received Menactra. (cdc.gov)
  • How can I report a case of GBS after Menactra or any vaccine? (cdc.gov)
  • As well, while the committee recommended that Menactra be administered at the same time as the newly licensed Tdap vaccine, no clinical trials had examined whether administering both vaccines simultaneously would be effective or even safe. (nvic.org)
  • As with Menactra vaccine, no vaccine efficacy studies had ever been completed nor had any studies determined whether or not the vaccine could reduce or eliminate nasopharyngeal carriage. (nvic.org)
  • A 2017 published study on Menactra (MenACWY-D) vaccine effectiveness found that overall, a single vaccine dose was between 51 and 80 percent effective. (nvic.org)
  • Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include children 2 years through 10 years of age. (news-medical.net)
  • We have been waiting for this expansion of use of Menactra(R) to younger children, since they too are at risk and may benefit from the vaccine. (news-medical.net)
  • The FDA's decision to license Menactra(R) vaccine for children 2 years through 10 years of age was based on safety and immunogenicity data from two large clinical studies. (news-medical.net)
  • Both studies were randomized, multi-center, active- controlled, modified double-blind clinical studies of children 2 years through 10 years of age comparing the safety and immunogenicity of Menactra(R) vaccine to Menomune(R)-A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined. (news-medical.net)
  • A third multi-center, open-label study of children 4 years through 6 years of age evaluated the antibody memory response to the vaccine in children who had been vaccinated previously with Menactra(R) vaccine approximately two years earlier. (news-medical.net)
  • In addition, compared to Menomune-A/C/Y/W-135 vaccine, Menactra(R) vaccine resulted in longer-term persistence of bactericidal antibody, production of high avidity antibody, and the establishment of immune memory. (news-medical.net)
  • Since its introduction in 2005 there has been strong acceptance by health- care providers and consumers for Menactra(R) vaccine. (news-medical.net)
  • Sanofi Pasteur will continue to work closely with the CDC's Advisory Committee on Immunization Practices regarding recommendations for children younger than 11 years of age, now that FDA has licensed Menactra(R) vaccine for use in children 2 years through 10 years of age. (news-medical.net)
  • For more information about Menactra(R) vaccine, please visit www.sanofipasteur.us . (news-medical.net)
  • Immunization providers can order Menactra(R) vaccine by visiting www.vaccineshoppe.com or calling 1-800-VACCINE (1-800-822-2463). (news-medical.net)
  • This is specifically for the quadrivalent (Menactra or Menveo) vaccine, which protects against types A, C, W and Y. (sharecare.com)
  • Antibodies to Menactra vaccine were measured by the Serum bactericidal. (clinicaltrials.gov)
  • Antibodies to Menactra vaccine were measured by the Serum bactericidal assay baby rabbit complement (SBA BR) Test. (clinicaltrials.gov)
  • Menactra vaccine antibody titers were determined in the immunogenicity analysis set. (clinicaltrials.gov)
  • Menactra vaccine is developed and manufactured by Sanofi Pasteur, the vaccines division of the Sanofi Aventis Group. (drugdevelopment-technology.com)
  • The FDA's decision to license the Menactra vaccine for adolescents and adults was based on safety and immunogenicity data from six pivotal studies, which included over 7,500 adolescents and adults who took the vaccine. (drugdevelopment-technology.com)
  • All vaccine immunogenicity measurements demonstrated strong immune responses to a single dose of the Menactra vaccine that were equivalent to a single dose of Sanofi Pasteur's Menomune®-A / C /Y/ W-135. (drugdevelopment-technology.com)
  • Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication f. (bio-medicine.org)
  • SNY ), announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include a two-dose schedule for infants and children 9 months through 23 months of age. (bio-medicine.org)
  • More than 36 million doses of Menactra vaccine have been distributed in the United States since its licensure in 2005. (bio-medicine.org)
  • The FDA approval of Menactra vaccine for infants was based on results of one Phase II and three Phase III modified single-blind, controlled, multicenter trials in which more than 3,300 infants from the United States received Menactra vaccine using a two-dose schedule, starting as young as 9 months of age. (bio-medicine.org)
  • The studies also showed that measles-mumps-rubella-varicella vaccine (MMRV) and pneumococcal conjugate vaccine (PCV7) can be administered concomitantly with Menactra vaccine in children. (bio-medicine.org)
  • In 2005, Menactra vaccine became the first quadrivalent meningococcal conjugate vaccine available in the United States for people ages 11 through 55 years of age. (bio-medicine.org)
  • Side effects following administration of Menactra vaccine include: pain, redness and swelling at the injection site, as well as headache or irritability and fatigue. (bio-medicine.org)
  • For Menactra vaccine prescribing information, please contact Sanofi Pasteur US. (bio-medicine.org)
  • National Network for Immunization Information: "Important Facts for Parents to Know About the Meningococcal Vaccine. (webmd.com)
  • An increase in public-private partnerships to support the development of vaccines at low cost, and rising immunization programs and government initiatives are some other major factors expected to boost the market growth. (bccresearch.com)
  • In 2015, the Advisory Committee on Immunization Practices recommended that 16- to 23-year-olds may be vaccinated with the serogroup B meningococcal (MenB) vaccine on the basis of individual clinical decision-making (Category B). We assessed the following among US pediatricians and family physicians (FPs): (1) practices regarding MenB vaccine delivery, (2) factors influencing a decision to recommend the MenB vaccine, and (3) factors associated with discussing the MenB vaccine. (aappublications.org)
  • In 2015, the Advisory Committee on Immunization Practices recommended 16- to 23-year-olds may be vaccinated with serogroup B meningococcal (MenB) vaccine on the basis of individual clinical decision-making (Category B). Little is known about how primary care physicians are adopting these recommendations. (aappublications.org)
  • The ACIP recommends immunization with meningococcal vaccine of all adolescents 11 through 18 years of age followed by a one-time booster dose of the vaccine 5 years later through age 21 years. (aetna.com)
  • In the spring of 2005, when the CDC's Advisory Committee on Immunization Practices (ACIP) voted that all 11-12 year olds be administered the vaccine, it acknowledged that immunogenicity data was not sufficient enough to determine the vaccine's effectiveness. (nvic.org)
  • In toddlers, only one dose of the MCC vaccine is required for routine immunization. (nih.gov)
  • The vaccine first received FDA licensure in 2005 for immunization of adolescents and adults 11 years through 55 years of age. (news-medical.net)
  • Attempting to overcome this problem by repeated immunization results in a diminished, not increased, antibody response, so boosters are not recommended with this vaccine. (wikipedia.org)
  • Their guidelines on the newly-licensed vaccines align with previous recommendations issued by the CDC's Advisory Committee on Immunization Practices . (healio.com)
  • On Oct. 27, the Advisory Committee on Immunization Practices (ACIP) voted to add the booster -- following an initial dose at age 11 or 12 -- after evaluating evidence from case-control and serologic studies indicating that protection from the vaccine wanes within five years. (biospace.com)
  • Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine-Advisory Committee on Immunization Practices, 2016. (pfizerpro.com)
  • Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. (pfizerpro.com)
  • An adverse event is any health problem that occurs after immunization that may or may not be related to the vaccine. (hamilton.ca)
  • The meningococcal conjugate vaccine (MenACWY) protects against four types of meningococcal bacteria (types A, C, W, and Y). It is recommended for all kids and teens age 11 and older. (kidshealth.org)
  • The MenACWY vaccine is very effective at protecting against four strains of the bacteria, while the MenB vaccine protects against a fifth strain. (kidshealth.org)
  • This vaccine does not contain live bacteria. (nationwidechildrens.org)
  • Further, data was not available to determine whether the vaccine could reduce or eliminate vaccine type meningococcal bacteria from the nasopharyngeal region and prevent persons who carried the bacteria from spreading it to others. (nvic.org)
  • Meningococcal polysaccharide vaccine is used to prevent infection caused by meningococcal bacteria. (drugs.com)
  • Meningococcal polysaccharide vaccine contains four of the most common types of meningococcal bacteria (A, C, W, and Y). (drugs.com)
  • Fortunately, there is a vaccine to protect your child against many of the infections caused by the meningococcal bacteria. (youngwomenshealth.org)
  • The meningococcal bacteria is usually spread by coming in contact with respiratory secretions when an infected person coughs or sneezes or by having contact with saliva when drinking from a water bottle, sharing cigarettes, and kissing. (youngwomenshealth.org)
  • College students or anyone living in crowded living conditions are particularly at risk because the meningococcal bacteria are easily spread from one person to another. (youngwomenshealth.org)
  • This vaccine contains four common strains of group B meningococcal bacteria. (cigna.com)
  • The meningococcal vaccine is very effective at protecting against four strains of the meningococcal bacteria. (rchsd.org)
  • Meningococcal bacteria can infect the blood, spinal cord, and brain. (cardiosmart.org)
  • The vaccine contains four of the most common types of meningococcal bacteria. (cardiosmart.org)
  • The meningococcal quadrivalent vaccine, given in Grade 7, protects against four strains of the bacteria: A, C, Y, and W-135 and is 80 to 85 per cent effective for teenagers. (toronto.ca)
  • Meningococcal polysaccharide diphtheria conjugate vaccine is an active immunizing agent used to prevent infection by certain groups of meningococcal bacteria. (mayoclinic.org)
  • The vaccine works by causing your body to produce its own protection (antibodies) against the bacteria. (mayoclinic.org)
  • The following information applies only to the meningococcal vaccine used for meningococcal bacteria Groups A, C, Y, and W-135. (mayoclinic.org)
  • A potential problem however is that bacteria constantly mutate and produce new strains with alterations in the antigens that reduce recognition by vaccine antibodies and escape protection. (news-medical.net)
  • We are very pleased to see that it looks like the vaccine has the potential to cover most of the strains of meningococcal Group B bacteria currently circulating in the U.S.," said lead study author Gowrisankar Rajam, Ph.D., health scientist at CDC. (asm.org)
  • These vaccines are composed of proteins found on the surface of the bacteria. (immunize.org)
  • No currently available meningococcal vaccine contains live meningococcal bacteria. (immunize.org)
  • vaccine must be used for all doses. (cdc.gov)
  • To immunise their babies against the B strain, parents have to pay between $125 and $150 per dose, with up to four doses needed, and the ACWY vaccine costs between $38 and $120. (change.org)
  • Multiple doses of serogroup B meningococcal vaccine are needed and the same brand must be used for all doses. (infectioncontroltoday.com)
  • Our patient is starting college with no documented doses of meningococcal ACWY vaccine and has had titers drawn. (immunize.org)
  • Can we accept this titer in lieu of documented MenACWY vaccine doses? (immunize.org)
  • At present, the developed conjugant Hib vaccine is proved to be safe and effective, 90-99% of children will produce antibody of protection after 3 doses. (clinicaltrials.gov)
  • The purpose of the study is to evaluate the immune responses of UK infants after one or two doses of pneumococcal conjugate vaccine or one or two doses of three different types of meningoc. (bioportfolio.com)
  • Revised recommendations are for children and adolescents 11 through 18 years of age to receive two doses of meningococcal vaccine. (uintacounty.com)
  • After good Phase III trial results, Novartis announced it will submit Menveo (Meningococcal Group A, C, W135 and Y conjugate vaccine) for infants aged at least two months for approval. (medicalnewstoday.com)
  • On approval, Menveo would be the only meningococcal quadrivalent conjugate vaccine for infants over two months of age on the market. (medicalnewstoday.com)
  • This outcome measure was analyzed on live births reported with MCM, for subjects who were exposed to Menveo vaccine within 28 days prior to conception. (clinicaltrials.gov)
  • This outcome measure was analyzed on live births reported with MCM, for subjects who were exposed to Menveo vaccine during the first trimester of pregnancy .The prevalence estimate of MCM was calculated as proportions of live births with MCM from the total number of live births. (clinicaltrials.gov)
  • Menveo, GlaxoSmithKline) contain meningococcal conjugate in which the surface polysaccharide is chemically bonded ('conjugated') to a protein to produce a robust immune response to the polysaccharide. (immunize.org)
  • People with certain chronic conditions appear to be at increased risk of developing meningococcal infection. (cdc.gov)
  • This vaccine will not treat an active infection that has already developed in the body. (drugs.com)
  • In the case of a more severe illness with a fever or any type of infection, wait until you get better before receiving this vaccine. (drugs.com)
  • Children and people who have higher risks of meningococcal infection may need a repeat dose of this vaccine. (drugs.com)
  • Children and people who have higher risks of meningococcal infection may need a repeat dose of this vaccine 2 or 3 years after receiving the first shot. (cardiosmart.org)
  • No vaccine is available in the United States for protection against infection from serogroup B. (news-medical.net)
  • The hard to diagnose meningococcal B infection which starts with symptoms similar to cold and flu and then develops into a deadly rash is one of the greatest fears parents face. (news.com.au)
  • The rate of these diseases peak in adolescence and early adulthood and are more likely to occur in persons with certain diseases or conditions that make them more susceptible to a meningococcal infection or more likely to develop serious problems from a meningococcal infection. (mayoclinic.org)
  • They have certain diseases or conditions that make them more susceptible to a meningococcal infection or more likely to develop serious problems from a meningococcal infection. (mayoclinic.org)
  • Babies and adolescents are the most at risk of contracting meningococcal infection and alarmingly up to 20 percent of cases result in fatality. (news-medical.net)
  • Bacterial vaccines contain key components from the outside of the bacterium which the body makes antibodies against without causing any infection. (news-medical.net)
  • If the meningococcal vaccine doesn't protect my child, do I have any other options for preventing meningococcal infection? (nvic.org)
  • There are no studies of 4CMenB vaccine in pregnant or lactating women, persons less than 2 months and over 55 years of age, persons with a chronic medical condition and those with previous meningococcal infection. (canada.ca)
  • One of the articles cited, written by Dr. Mike Godfrey, is particularly interesting and documents the connection of meningococcal "infection" and lack of vitamin C , a common nutrient that seems deficient in a sizeable proportion of populations world wide. (newmediaexplorer.org)
  • Appropriate studies have not been performed on the relationship of age to the effects of meningococcal polysaccharide diphtheria conjugate vaccine in adults older than 55 years of age. (mayoclinic.org)
  • The vaccine is not recommended for anyone with a serious reaction to diphtheria or tetanus toxoid (found in some vaccines). (toronto.ca)
  • Has received full series of diphtheria, tetanus, and pertussis (DTP)/DTaP vaccines and oral poliomyelitis virus (OPV)/IPV vaccines per country-specific recommendations applicable at the time of receipt. (pfizer.com)
  • 4CMenB vaccine has been given simultaneously with a hexavalent tetanus diphtheria containing infant vaccine, heptavalent pneumococcal conjugate vaccine (PCV7), serogroup C meningococcal vaccine and MMRV. (canada.ca)
  • The 1940-70s literature supports this with parenteral ascorbic acid (AA) capable of destroying diphtheria, tetanus, salmonella, gas gangrene (clostridium) and meningococcal endotoxins. (newmediaexplorer.org)
  • You should not receive this vaccine if you have had a severe allergic reaction to meningococcal or diphtheria vaccines. (limamemorial.org)
  • The decision to get the MenB vaccine is made by the teen, their parents, and their doctor. (kidshealth.org)
  • Kids 10 years and older with these risk factors also should get the MenB vaccine. (kidshealth.org)
  • For those without risk factors, the decision to receive the MenB vaccine should be made together by teens, their parents, and the doctor. (kidshealth.org)
  • During routine visits, 51% of pediatricians and 31% of FPs reported always or often discussing MenB vaccine. (aappublications.org)
  • We found that 73% of pediatricians and 41% of FPs currently administered the MenB vaccine. (aappublications.org)
  • A minority of physicians are discussing MenB vaccine during routine 16- to 18-year-old visits. (aappublications.org)
  • Two serogroup B meningococcal (MenB) vaccines have been licensed by the Food and Drug Administration in the United States and approved for use in persons aged 10 to 25 years: MenB-FHbp (Trumenba) and MenB-4C (Bexsero). (aappublications.org)
  • Martinez told AAFP News that the MenB vaccines weren't on her radar before she started her fellowship. (aafp.org)
  • In their FAQ, the vaccine science fellows touched on a number of issues surrounding the MenB vaccines. (aafp.org)
  • The incidence of MenB is highest in children age 5 or younger, with an estimated 75-100 cases per year, but the MenB vaccines are not licensed in the United States for this age group, the FAQ said. (aafp.org)
  • The two MenB vaccines are fairly pricey, with Trumenba's three-dose series carrying a CDC private sector price of $115.75 per dose or $347.25 for the series, the fellows said. (aafp.org)
  • these persons should receive an MenB vaccine series if their treating health care providers, in consultation with their local health or state departments, determine they are appropriate candidates on the basis of CDC criteria. (healio.com)
  • A severe allergic reaction to a previous dose of MenB vaccine or any of its components is a contraindication. (healio.com)
  • The two new MenB vaccines, Trumenba and Bexsero contain protein antigen, FHbp, and are effective against the majority of MenB strains. (news-medical.net)
  • Researchers used a laboratory test called the Meningococcal Antigen Typing System (MATS) to study the coverage potential of the MenB-4C vaccine, which was approved by the Food and Drug Administration in January 2015 for use in individuals ages 10-25 years. (asm.org)
  • The MATS test showed that 91 percent of these US bacterial strains express antigens similar to those contained in the MenB-4C vaccine, with an estimated coverage ranging from 88 percent to 97 percent each year. (asm.org)
  • Significant variation in the likelihood of MenB vaccine receipt correlated with sociodemographic, clinical, and provider factors. (mdedge.com)
  • In an effort to identify sociodemographic and provider factors associated with MenB vaccine receipt, Dr. Feemster and her associates conducted a cross-sectional study of 85,789 Philadelphia youth aged 16-18 years who had a record in the KIDS Plus II Philadelphia database between Oct. 31, 2015 and July 31, 2017. (mdedge.com)
  • P less than .0001) also were less likely to receive the MenB vaccine, reported Dr. Feemster, who is also director of research for Children's Hospital of Philadelphia's Vaccine Education Center, and her colleagues. (mdedge.com)
  • They also speculated that variation in MenB receipt across different providers "may reflect different recommendation practices, perceived need for MenB vaccines in a provider's patient population, or clinic-level purchasing decisions. (mdedge.com)
  • Two serogroup B meningococcal group B vaccines (Bexsero and Trumenba) have been licensed by the Food and Drug Administration (FDA). (medlineplus.gov)
  • The case, which will come before the Commercial Court today, involves the Pfizer vaccine Trumenba, which is currently licensed in the US and which is planned to make available globally. (irishtimes.com)
  • The findings, published today in the journal ' Frontiers in Microbiology ', could have major implications for the current meningococcal group B vaccines, Trumenba and Bexsero, both of which contain Factor H binding protein (FHbp), a lipoprotein found on the bacterium's surface. (news-medical.net)
  • The Trumenba vaccine currently used to protect against meningococcal group B is monovalent, it comprises two versions of the same antigen. (news-medical.net)
  • Therefore the antigen in the Trumenba vaccine is presented in a different manner to the native antigen produced by most strains. (news-medical.net)
  • The test currently used to predict which meningococcal isolates will be targeted by Trumenba measures the abundance of FHbp on the cell surface since a critical amount is needed for antibodies to bind the cell and aid killing. (news-medical.net)
  • The data reported from these tests show that some strains with sufficient FHbp levels are surprisingly not susceptible to killing by Trumenba vaccine antibodies. (news-medical.net)
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. (pfizerpro.com)
  • Sanofi Pasteur, the manufacturer of meningococcal polysaccharide vaccine (Menomune), announced in February 2017 that it is discontinuing production of the vaccine. (cdc.gov)
  • With the discontinuation of Menomune, no meningococcal polysaccharide vaccines licensed for use in people 56 years of age are available in the United States. (cdc.gov)
  • Menomune - A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W- 135 Combined, is a vaccine for subcutaneous injection. (rxlist.com)
  • Menomune - A/C/Y/W-135 vaccine consists of a sterile lyophilized preparation of the group-specific polysaccharide antigens from N meningitidis, Group A, Group C, Group Y, and Group W-135. (rxlist.com)
  • Menomune - A/C/Y/W-135 vaccine is approved for use in persons 2 years of age and older. (rxlist.com)
  • Using a suitable sterile needle and syringe and aseptic technique, withdraw (Refer to Figure 4) and administer a 0.5 mL dose of Menomune - A/C/Y/W-135 vaccine by subcutaneous injection. (rxlist.com)
  • Insert the syringe needle through the stopper of the vial of lyophilized Menomune vaccine component and inject the diluent into the vial. (rxlist.com)
  • The pure polysaccharide vaccine Menomune, MPSV4, was discontinued in the United States in 2017. (wikipedia.org)
  • Meningococcal polysaccharide vaccine (MPSV-4), Menomune, has been available since the 1970s. (wikipedia.org)
  • As with all polysaccharide vaccines, Menomune does not produce mucosal immunity, so people can still become colonised with virulent strains of meningococcus, and no herd immunity can develop. (wikipedia.org)
  • What is meningococcal polysaccharide vaccine (Menomune A/C/Y/W-135)? (rxlist.com)
  • What are the possible side effects of this vaccine (Menomune A/C/Y/W-135)? (rxlist.com)
  • What is the most important information I should know about this vaccine (Menomune A/C/Y/W-135)? (rxlist.com)
  • What should I discuss with my healthcare provider before receiving this vaccine (Menomune A/C/Y/W-135)? (rxlist.com)
  • December 7, 2011 - Adolescents should be routinely immunized with the quadrivalent meningococcal conjugate vaccine (MCV4) at 11 or 12 years of age and receive a booster dose at age 16 years, according to updated guidelines in an American Academy of Pediatrics (AAP) policy statement published online November 28 and in the December print issue of Pediatrics . (medscape.com)
  • The MenACWY vaccine has been licensed in the United States since 2005 and is recommended for routine use among adolescents from 11 to 18 years of age. (aappublications.org)
  • Some states have introduced a free ACWY combined vaccine program for adolescents, the most at risk group, however this isn't consistent across all states. (change.org)
  • This policy statement updates the AAP recommendations for use of meningococcal vaccines in children and adolescents. (aappublications.org)
  • The decrease started before the availability of the meningococcal conjugate vaccine and recommendations for routine meningococcal vaccine use in adolescents. (aappublications.org)
  • Adolescents should be routinely immunized at 11 to 12 years of age and given a booster dose at 16 years of age with a quadrivalent conjugated meningococcal vaccine. (aappublications.org)
  • The vaccines may be administered, though not routinely, to adolescents and young adults aged 16 through 23 to provide short-term protection. (healio.com)
  • MedPageToday -- A new recommendation for adolescents to receive a meningococcal vaccine booster at age 16 became official this week. (biospace.com)
  • Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. (pfizerpro.com)
  • GlaxoSmithKline's meningococcal group B vaccine Bexsero is currently the only available in most markets and is in such high demand that the multinational has been struggling to increase supply. (irishtimes.com)
  • Bexsero is manufactured by Novartis Vaccines and Diagnostics Inc. (drugstorenews.com)
  • Funding, material and support for the study was provided by GlaxoSmithKline Biologicals SA, manufacturer of the Bexsero meningococcal vaccine. (asm.org)
  • Numerous studies have demonstrated the immunogenicity and clinical efficacy of the A and C vaccines. (cdc.gov)
  • Clinical trials on Menactra's efficacy were not a requirement for FDA licensing and the vaccine's immunogenicity was based on blood antibody testing completed 28 days following vaccine administration. (nvic.org)
  • Immunogenicity, however, is not necessarily indicative that either available Men B vaccine is, in fact, effective against any of the various meningococcal group B strains that may be circulating in the environment. (nvic.org)
  • Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. (nih.gov)
  • So it is meaningful to improving vaccine immunogenicity, to provide high levels of long-term protection and to reduce the number of injections. (clinicaltrials.gov)
  • Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. (bioportfolio.com)
  • Nationally there are up to 250 cases of meningococcal B each year and around 10% of patients die and 20% are left with permanent disabilities. (news.com.au)
  • If you have ever had a life-threatening allergic reaction after a previous dose of meningococcal ACWY vaccine, or if you have a severe allergy to any part of this vaccine, you should not get this vaccine. (medlineplus.gov)
  • 2019. Vaccine information statement: Meningococcal ACWY VIS. (babycenter.com)
  • Has had an allergic reaction after a previous dose of meningococcal ACWY vaccine , or has any severe, life-threatening allergies . (cigna.com)
  • People who are moderately or severely ill should usually wait until they recover before getting meningococcal ACWY vaccine. (cigna.com)
  • Redness or soreness where the shot is given can happen after meningococcal ACWY vaccine. (cigna.com)
  • Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers. (bioportfolio.com)
  • These vaccines do not protect against meningococcal groups B and X. Serogroup B vaccines have been extracted from selected outbreak strains and are currently used in some countries to limit outbreaks. (who.int)
  • The Global Meningococcal Vaccines Market study report will provide a valuable insight with an emphasis on global market including some of the major players such as Biomed Pvt. (bccresearch.com)
  • The global meningococcal vaccines market garnered $1.93 million in 2018, and is expected to generate $4.19 billion by 2026, registering a CAGR of 9.5% from 2019 to 2026. (medgadget.com)
  • The report offers a detailed segmentation of the global meningococcal vaccines market based on vaccine serotype, vaccine type, end user, and region. (medgadget.com)
  • The vaccine consists of 50 ug each of the respective purified bacterial capsular polysaccharides. (cdc.gov)
  • The MenACWY meningococcal vaccine contains polysaccharide capsular antigens that coat the outside of this bacterial species. (news-medical.net)
  • Antibodies against the group A and C polysaccharides decline markedly over the first 3 years following a single dose of vaccine (5,10-13). (cdc.gov)
  • it was significant only for antibodies to meningococcal C antigen (P=0.03), although the geometric mean titre was still over sevenfold greater than prevaccination values. (bmj.com)
  • It is unclear at the moment whether the altered presentation affects the ability of vaccine-elicited antibodies to kill these strains. (news-medical.net)
  • Development of the 4-component meningococcal serogroup B vaccine (4CMenB) has required new assays for the reliable evaluation of the expression and cross-reactivity of those specific antigen variants that are predicted to be targeted by bactericidal antibodies elicited by the vaccine in different isolates. (hindawi.com)
  • There are currently no data on the persistence of bactericidal antibodies induced by use of this vaccine in infants. (cmaj.ca)
  • Mapping of epitopes recognized by functional monoclonal antibodies (mAbs) is essential for understanding the nature of immune responses and designing improved vaccines, therapeutics, and diagnostics. (rcsb.org)
  • A child who has had a life-threatening allergic reaction to a previous dose of meningococcal vaccine should not be vaccinated with it again. (babycenter.com)
  • 3 However, by October of 2010, five years after the initial approval vote, ACIP voted to add a booster dose of meningococcal vaccine at age 16. (nvic.org)
  • Sanofi Pasteur is a vaccine industry leader with a strong heritage of meningococcal vaccine development. (bio-medicine.org)
  • MenHibrix® [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine] was discontinued in the U.S in 2016 (GSK, 2016). (aetna.com)
  • Y) conjugate vaccine (HibMenCY-TT [MenHibrix, GlaxoSmithKline Biologicals, Research Triangle Park, NC]), which is also approved as a vaccine for Haemophilus influenzae type b ( Table 1 ). (aappublications.org)
  • Be the first to review Haemophilus B-Meningococcal Conj Vaccine and share your experience with other Everyday Health users. (everydayhealth.com)
  • We're sorry, but there are currently no reviews for Haemophilus b-meningococcal conj vaccine. (everydayhealth.com)
  • Combined haemophilus influenzae type B (HIB) plus monovalent C meningococcal vaccine. (who.int)
  • The objective of this study is to evaluate the safety of the group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine. (clinicaltrials.gov)
  • Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial. (bioportfolio.com)
  • The vaccine is also recommended for infants and children in high-risk situations, including those traveling to certain countries as well as college freshmen living in dormitories and military recruits living in barracks. (babycenter.com)
  • In 2016, they approved the vaccine in infants six weeks of age and older, and it has been approved in other countries including Canada and Australia, among others. (wikipedia.org)
  • vaccine GSK134612 compared to the licensed vaccines MenC-CRM197 and MenC-TT in infants of 2 months of age. (bioportfolio.com)
  • Although meningococcal infections are rare, they are very serious diseases that can cause death. (youngwomenshealth.org)
  • The incidence of all meningococcal B serotype infections in the United States is estimated to be about 200 cases per year among persons of all ages,' the FAQ said. (aafp.org)
  • The latent scorbutic state can then be converted into frank scurvy by infections (and even vaccines), and under such conditions hemorrhagic phenomena are frequent. (newmediaexplorer.org)
  • Has had an allergic reaction after a previous dose old of meningococcal B vaccine , or has any severe, People with certain medical conditions that affect life-threatening allergies . (cdc.gov)
  • of a vaccine causing a severe allergic reaction, other serious injury, or death. (cdc.gov)
  • Severe allergic reactions are rare but possible with any vaccine. (babycenter.com)
  • You should not receive this vaccine if you have ever had an allergic reaction to a meningococcal vaccine. (drugs.com)
  • Before receiving meningococcal polysaccharide vaccine, tell your doctor if you have a weak immune system, if you are allergic to latex rubber, or if you are receiving steroids, chemotherapy, or radiation treatment. (cardiosmart.org)
  • You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first shot. (rxlist.com)
  • As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death. (healthychildren.org)
  • Generally there is little or no reaction to a vaccine, but in some cases the vaccine may cause an allergic reaction or a temporary, mild illness. (sharecare.com)
  • The antibody responses to each of the four polysaccharides in the quadrivalent vaccine are serogroup-specific and independent. (cdc.gov)
  • We received responses from 40 in the combined groups A and B and 40 in group C. Antibody response to meningococcal A, meningococcal C, and typhoid Vi antigens was assessed by radioimmunoassay. (bmj.com)
  • Instead, vaccine efficacy was based on 'complement mediated antibody killing' detected in the serum of individuals who received the vaccines, a surrogate measure of protection,' the FAQ said. (aafp.org)
  • In study A, the PsA-TT group had higher antibody titers at week 40 than the PsACWY group and had obvious immunologic memory after receiving a polysaccharide booster vaccine. (nih.gov)
  • The PsA-TT vaccine elicited a stronger response to group A antibody than the PsACWY vaccine. (nih.gov)
  • The vaccine that has been developed to target strain B, called 4CMenB, includes four components that target various parts of the bacterium. (medicalnewstoday.com)
  • MenACWY-CRM" is also a Meningococcal Conjugate Vaccine, and works similarly to MenACWY-D. (youngwomenshealth.org)
  • The risk you take with monovalent vaccines is that isolates may have previously acquired mutations in the target or go on to acquire new mutations such that the target changes significantly from that contained within the formulation. (news-medical.net)
  • This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines. (centerwatch.com)
  • A single dose of monovalent A meningococcal vaccine is licensed for individuals 1-29 years of age. (who.int)
  • What Are the Possible Side Effects of Meningococcal Vaccines? (kidshealth.org)
  • Cite this: AAP Updates Meningococcal Vaccine/Booster Dose Guidelines - Medscape - Dec 07, 2011. (medscape.com)
  • Study authors concluded that a booster dose of meningococcal conjugate vaccine would likely provide more long term vaccine acquired immunity, but also stated that "the additional impact gained from the booster dose in terms of cases prevented is likely to be limited. (nvic.org)
  • It questioned how long the vaccine would offer protection before a booster was needed. (news.com.au)
  • Meningococcal vaccine (MCV4) is recommended for all children ages 11 to 12, with a booster dose at age 16. (sharecare.com)
  • As adults, we receive flu vaccines or may need a booster of childhood vaccines to retain immunity. (sharecare.com)
  • Mozambique introduced 10-valent pneumococcal conjugate vaccine (PCV10) in April 2013, using a 3-dose schedule without a booster. (bioportfolio.com)
  • There are two types of vaccines: MPSV4 and MCV4. (sheknows.com)
  • The vaccines are MenACWY (meningococcal conjugate vaccine) and MPSV4 (meningococcal polysaccharide vaccine). (healthline.com)
  • MPSV4″ stands for Meningococcal Polysaccharide Vaccine. (youngwomenshealth.org)
  • magazine is asking the Federal Government to provide FREE vaccines for all five strains of meningococcal - A,B,C,W,Y. (change.org)
  • Meningococcal serogroup B strains, however, are quite diverse, and as a result, vaccine effectiveness is difficult to assess. (nvic.org)
  • Vaccine effectiveness. (nih.gov)
  • The government's expert Pharmaceutical Benefits Advisory Committee (PBAC) has rejected a subsidy call and said there were "multiple uncertainties" about the clinical effectiveness of the vaccine. (news.com.au)
  • He says he hopes the PBAC has taken this into consideration when making its decision on the cost effectiveness of the vaccine. (news.com.au)
  • Vaccine effectiveness decreases over time. (toronto.ca)
  • The 4CMenB vaccine is an immunogenic vaccine, though its effectiveness, impact on carriage and the duration of protection remains unknown. (canada.ca)
  • Further research, evaluation and surveillance will be required to determine the duration of protection, the efficacy or effectiveness of 4CMenB vaccine, its ability to induce herd protection, and the risk of adverse events with widespread use. (canada.ca)
  • A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. (pfizer.com)
  • Conjugated polysaccharide vaccines use a T-cell-dependent mechanism that results in a more robust primary immune response and immunologic memory and boosting potential, as compared with polysaccharide-only vaccines that use a T-cell independent mechanism. (aappublications.org)
  • The contributors-leading scientists, clinicians, and public health physicians-describe in detail the many approaches to vaccine design, as well as the assessment of immune response to vaccine candidates and novel vaccine formulations. (springer.com)
  • The immune response to routine infant vaccines and the 4CMenB vaccine does not appear to be affected when these vaccines are administered simultaneously. (canada.ca)
  • Continued surveillance is required to monitor the changing prevalence of these vaccine antigens. (eurosurveillance.org)
  • More than half of the covered strains could be targeted by two or more antigens in the vaccine, the investigators found. (asm.org)
  • The vaccine is protective against strains that express antigens contained in the vaccine at sufficient levels. (canada.ca)
  • When should my child get the meningococcal (MCV4) vaccine? (sharecare.com)
  • That's why 2015-2016 AAFP Vaccine Science Fellows Nina Ahmad, M.D., and Melissa Martinez, M.D., created a frequently asked questions (FAQ) document about the vaccines for family physicians as part of their fellowship. (aafp.org)
  • The 2015-2016 AAFP Vaccine Science Fellows created a frequently asked questions resource for family physicians about the two serogroup B meningococcal vaccines. (aafp.org)
  • Amid the COVID-19 crisis, the global market for Meningococcal Vaccines estimated at US$3.4 Billion in the year 2020, is projected to reach a revised size of US$7.2 Billion by 2027, growing at a CAGR of 11.3% over the analysis period 2020-2027. (researchandmarkets.com)
  • The Meningococcal Vaccines market in the U.S. is estimated at US$1 Billion in the year 2020. (researchandmarkets.com)
  • Mild side effects of the meningococcal vaccines include redness and soreness around the injection area and, in some cases, a mild fever. (sheknows.com)
  • Minimal side effects of the vaccine may include mild pain and redness at the injections site. (citadel.edu)
  • Common side effects include pain and redness where the vaccine was given, headache, and feeling tired or unwell for a short time after receiving the vaccine. (toronto.ca)
  • The vaccines may cause mild and infrequent side effects, such as redness and pain at the injection site lasting up to two days. (who.int)

No images available that match "meningococcal vaccines"